header logo image


Page 11«..10111213..2030..»

Archive for the ‘Molecular Genetics’ Category

Whitby student welcomes A-level U-turn – but still left in limbo over his future – Whitby Gazette

Thursday, August 20th, 2020

A-level student Kilian Robinson.

Kilian Robinson, 18, of Egton, consistently achieved the highest possible grades for his subjects Biology, Chemistry and Maths over the past two years.

But he was horrified on Thursday to discover that his centre assessment grades had been reduced from A*A*A* to ABB by the controversial Government algorithm, despite him not once attaining anything lower than an A.

He said today (Tues) that Imperial College London had indicated they would keep his place on a Biological Scienes course open to him if he successfully appealed.

Yesterday's Governments U-turn means Kilian has attained his grades and fulfilled his side of the bargain.

He is now waiting to hear back from Imperial College London, having emailed them after the dramatic climbdown was announced.

They said they would honour my offer if I got the grades now Ive got them," he said.

The fight isnt over. Everyone is anxious about it and what if the course is full?

Its a massive problem, yes Ive got my grades but its still to be resolved.

Kilian was offered a place on a Molecular Genetics course in Edinburgh, despite not his results being initially downgraded, but he declined as he has set his heart on a place at Imperial College London.

Read more:
Whitby student welcomes A-level U-turn - but still left in limbo over his future - Whitby Gazette

Read More...

Coronavirus: Cold temperatures are where Covid-19 thrives – Stuff.co.nz

Thursday, August 20th, 2020

This story was originally published on Newsroom.co.nz and is republished with permission

With investigations into a coolstore and freight as a potential pathway for the latest outbreak of Covid-19, what does science say about surfaces and refrigeration?

Surfaces at a Mount Wellington coolstore are being tested for Covid-19 in an effort to uncover the route of the virus back into the community.

Ryan Anderson/Stuff

Americold in Mount Wellington, Auckland, where a south Auckland man with coronavirus works.

A worker at the coolstore has tested positive for the disease. How he caught it is still a mystery. The possibility it could have come in on overseas freight arriving at the coolstore is being investigated.

Were not ruling that out, said Director-General of Health Ashley Bloomfield, We want to get to the bottom of that.

READ MORE:* Coronavirus: Extension to Covid-19 lockdown likely, says disease modelling expert* Coronavirus: Rapid 'cluster busting' to find Covid-19 outbreak source could nip other clusters in the bud* Coronavirus: Auckland cool storage facility tested over concern Covid-19 entered NZ via freight* Coronavirus: Aucklanders should be wearing masks, experts say

The coolstore environment has been swabbed and test results are expected back today.

Yesterday, three other workers from the coolstore returned positive tests for Covid-19.

It's possible the workers were either infected by contaminated goods, or the virus was brought into the workplace after it was caught elsewhere, possibly by the man who was first diagnosed.

Two branches of the coolstore have been closed. One in Mount Wellington, where the man worked, and another close to Auckland Airport.

Genomic sequencing is still underway, but as of yesterday afternoon there hasnt been a link between genome patterns of cases in border quarantine and the genome pattern of the coolstore-related cases.

University of Auckland professor Shaun Hendy said the fact the source of the outbreak hadnt been identified yet was concerning.

MYTCHALL BRANSGROVE/STUFF

Tests are still ongoing to trace the pandemics source.

To date, the genomic information suggests this cluster is not linked to a managed isolation and quarantine facility. The business itself is linked to international freight, air and sea, which does suggest that this is a possible entry route, whether via packaging, or more likely, via person-to-person.

Like many things Covid-19 related, the science of transmission isnt clear-cut; what studies have been done are often laboratory-based.

Surface transmission is considered a lower risk for virus transmission than person-to-person contact but cold environments, such as meat works, have been at the centre of overseas clusters.

Cant touch this

New Zealands news came as China has again claimed it has found the virus on the outer packaging of frozen prawns imported from Ecuador.

Chinas state television said it was found during a routine inspection of a restaurant in Wuhu city.

Its not the first report of this in China. Since July, several other Chinese cities have also reported cases, including the port cities of Xiamen and Dalian leading to imports from three suppliers being suspended.

After nucleic acid sequence analysis and expert judgment, the test results suggested that the container environment and the outer packaging of the goods of the three companies were at risk of contamination by the new coronavirus, and the companies food safety management system was not in order, the General Administration of Customs said in a statement.

The director of the organisation, Bi Kexi, told reporters: "Experts believe that the results do not mean they are contagious but that the companies' food safety management systems are not well implemented," Bi Kexin, director General Administration of Customs said.

For international packaging to be the cause of this outbreak, a chain of events would need to have taken place. Enough of the virus landing - on packaging - perhaps through a person coughing droplets onto a surface - would be the first step. The droplets would need to remain viable throughout the journey to the New Zealand coolstore.

Then the virus on the packaging would need to find a pathway to a person, possibly through someone touching the package and then touching their face.

Studies have been done on how long the virus survives on different surfaces. Traces of the virus were detected on plastic and steel up to three days after contamination and on cardboard for up to one day.

In chilled conditions, the virus can survive longer. One study looking at the survival time of the virus in a test tube found at 4C, the virus survived for 14 days. At 37C it lasted just one day.

The other factor is the amount of virus on a surface. A recent letter published in The Lancet suggests the risk of surface transmission has been exaggerated.

None of these studies present scenarios akin to real life situations, the letter said.

The Rutgers University professor of microbiology, biochemistry and molecular genetics Emanuel Goldmans issue was that in real life the amount of virus would likely be several orders of magnitude smaller.

While saying he believed in erring on the side of caution, he thought the risk was low.

In my opinion, the chance of transmission through inanimate surfaces is very small, and only in instances where an infected person coughs or sneezes on the surface, and someone else touches that surface soon after the cough or sneeze (within one - two hours).

While the risk is considered low, its still a possibility.

In a Chinese mall, several people caught the virus in January despite not being in direct contact with the one person at the mall who was known to have it. A restroom and elevator buttons were considered to be places where these people may have touched contaminated surfaces.

Covid and chill

Cold work environments have been at the centre of outbreaks. The exact reasons why arent clear, although theres plenty of speculation.

In the US 17,358 cases of coronavirus were recorded from meat and poultry factory workers.

An abattoir in Germany was closed after 1500 workers were infected and in Melbourne at least three abattoirs were closed after outbreaks occurred. Abattoir-related outbreaks have also occurred in the United Kingdom, France, Brazil, Denmark and the Netherlands.

There are a few factors likely to be at play and theyre not related to dead animals.

Physical distancing on a production line can be hard as often people work shoulder-to-shoulder. Shifts are long, and casualised employment can make people less likely to stay home when ill because they cant afford time off.

Background noise can mean shouting is needed to communicate, increasing the risk of droplet spread. Air filtration systems push air around, potentially spreading droplets further.

No sunlight and cold conditions extend the life of the virus.

The conditions at the New Zealand coolstore where cases have emerged may not be identical to overseas abattoirs, but there's a chance cold may play a role in giving any virus in the environment a chance to live longer.

This story was originally published on Newsroom.co.nz and is republished with permission

Read the original:
Coronavirus: Cold temperatures are where Covid-19 thrives - Stuff.co.nz

Read More...

Is it safe to send kids to school? Visit gyms? Attend a protest? N.C. experts weigh in. – Greensboro News & Record

Saturday, July 11th, 2020

RALEIGH As North Carolina prepared in late May to enter Phase Two of Gov. Roy Coopers plan to reopen the state in the midst of the coronavirus pandemic, we talked to doctors from UNC and Duke about which Phase Two activities they considered safe or risky.

For this follow-up two months later, we asked our experts how they felt about sending kids (or young adults) to school in the fall; about going to bars, gyms and bowling alleys; and about attending protests.

The first thing we learned from checking back with our experts is that their feelings about the activities we discussed in our first story havent changed much. If anything, most of our doctors held stricter opinions now.

On Saturday, North Carolina had nearly 1,100 people in hospitals with COVID-19 issues, marking the fifth consecutive day the state broke a record for hospitalizations, according to data from the N.C. Department of Health and Human Services. There were 1,093 hospitalizations on Saturday, and the number of positive confirmed cases of coronavirus hit an all-time, one-day high of 2,462 since the virus reached the state in early March.

Compared to May, the risk of being infected with this coronavirus has only increased, said Dr. David Alain Wohl, a professor at the Institute of Global Health and Infectious Diseases at UNC-Chapel Hill.

There are more people infected currently out and about, and many are not mask-wearing or physically distancing either, for reasons that are not evidence-based or because they are being neglectful.

Dr. Amir Barzin, professor and director of UNC Family Medicine Center, has also become more cautious since May.

A lot of what we talked about before still is very applicable to right now, Barzin said. If anything, Im understanding as a physician that this is a longer and longer course, and so my ethical responsibility as a doctor is to try to keep myself healthy and safe longer and longer. So if anything, maybe Ive become a bit more conservative.

In addition to Wohl and Barzin, we followed up with Dr. Tony Moody, associate professor in the Department of Pediatrics at Duke University School of Medicine and member of the Duke Human Vaccine Institute; and Dr. Sallie Permar, a professor of pediatric infectious disease, immunology and molecular genetics at the Duke School of Medicine. In our first round, we also spoke to Regina Petteway, director of Wake County Human Services. Petteway retired on July 1, so for our follow-up, we talked to Chris Kippes, Wake County Public Health division director.

There has been much discussion about reopening bars and gyms, so we asked our experts if those are places they would feel comfortable visiting.

For our experts, its a resounding no particularly in regard to bars.

Wohl told us no way when we asked about bars, and absolutely not when we asked about gyms. As for exercise, I exercise out of doors with others who I stay a generous distance from, Wohl said.

Moody was also a no on bars and gyms.

While I really like the socialization, the bar setting is exactly the kind of place where transmission may be easiest, Moody said. People may have lowered inhibitions, and they are usually in tight quarters, often talking directly into each others faces or ears, especially if conversation and music is loud.

Moody said that like bars, the activities in gyms are exactly those most likely to speed transmission.

People are breathing heavily and may be much less likely to wear a mask, both of which would facilitate virus spread into the air, Moody said.

Also, people may be touching their face more frequently and then depositing infectious particles on surfaces, and it is challenging to have people be scrupulous about cleaning surfaces after every use. Classes (spin, yoga, aerobics, etc.) where you have many people in a tight space are perfect for transmission.

Moody says for now he is working out at home and getting lots of outdoor exercise by biking and walking, making sure he can distance and avoid people.

Even then, he added, Ive taken to carrying a mask so that if I have to approach someone, I can cover up.

Barzin told us that he would definitely not visit a bar right now.

That is one of the absolute hard nos for me, he said, citing an atmosphere favorable to the potential spread of contagion.

Barzin said he understands bar owners desire to reopen, but worries about the long-term repercussions of opening too soon and then having an outbreak associated with a business.

But he said there is, in theory, a right way and a wrong way to reopen.

If you have the opportunity to be outdoors, if you put tables outdoors, that would make it more attractive, I think, Barzin said. It makes it more safe for the patrons. But right now, Im trying to limit exposure in confined areas for prolonged periods of time.

His feelings about gyms are similar.

I think, again, this is one of those situations where you get a lot of people confined, he said. Especially in a gym, people are exerting themselves, they are breathing harder ... that is not an area where Id spend a lot of time.

Permar is in agreement about bars and gyms.

The point of going to a bar, congregating and talking in a group of adults, is a high-risk setting for transmission, she said. Moreover, drinking and universal masking dont mix well. But I would like to be able to order takeout cocktails!

At gyms, the heavy breathing during a workout can be a high-risk setting for transmission, Permar said.

And masking could be seen as a challenge and may be less effective in this setting. Outdoor, spaced group workouts seem like a way for group physical activity to continue.

Kippes said he would not visit a bar at this time. He said he would visit a gym only if the gym was able to assure social distancing, require use of face masks/coverings and have procedures in place to keep equipment clean between individual usage.

The reason we asked this question which on the surface may seem a little random is because of the recent lawsuit in which owners of bowling alleys are demanding they be allowed to reopen. This week, Wake County Superior Court Judge James Gale said Gov. Roy Cooper didnt give good enough evidence why bowling alleys should remain closed.

Our health experts disagree.

Moody said he would probably not go bowling for some of the same reasons he wouldnt go to a bar or gym.

Bowling alleys are generally less crowded and the exertion level is lower, but the enclosed space is still an issue, he said.

Permar said she will avoid this type of indoor activity because it promotes a congregation of adults. (She is very hopeful that drive-in movies will make a comeback, though.)

Barzin also dislikes the idea of a lot of people in one area at the same time.

Bowling is not something we do on a regular basis and not something we would start doing at this time, he said.

Kippes says if the bowling alley was able to assure social distancing and require the use of face coverings, he would consider it.

Wohl was straight and to the point: No offense to bowling fans, but this seems like a really low priority during an ongoing pandemic.

Our experts were a little more mixed in their comfort level attending protests, but primarily agreed that it all depends on the circumstances.

Wohl warned against any mass gatherings, including protests, sporting events or political rallies, where masks are eschewed and people are packed closely together. These types of situations smack of a denial that there is a deadly contagious pathogen circulating in our country, he said.

And when you take those activities indoors, even worse, he said.

But if mask rules and distancing protocols are followed, and it takes place outdoors, Wohl is more comfortable with protests.

Demonstrations organized to promote distancing and face masks and are held in the open air, are less risky, he said. And given the importance of such protests at this moment, (they) are acceptable to me.

Kippes said he would attend an outdoor protest or rally if social distancing was maintained and all who attended wore face masks or coverings.

Permar said she is not only comfortable with attending outdoor protests, she has done it.

I would and have (attend a protest), while wearing a mask and distancing, she said. I support the important fight against systemic racism which has been amplified by these protests over the last few weeks.

Barzin said he supports protests, and feels that the ones where people are spaced and wearing face coverings are a little bit safer in terms of something I would consider doing.

If it was a large mass protest where they werent requiring those things, even though I would feel like the social issues are the correct ones to participate in, I dont know if I would be out there participating in that just based off the fact that my job requires me to be healthy. I want to provide good care for people, I dont want to put any extra risk on myself or my family or my patients.

Moody was conflicted about protests, but echoed Barzins concerns about putting his patients at risk.

Being outdoors is helpful, the crowds are not, he said. I am very supportive of our right as Americans to protest and view the choice to do so, even at a time of pandemic, as intensely personal.

Moody said he has considered attending protests in Raleigh, but in the end opted not to because he feels an obligation to his patients to be well when he sees them.

However, I also have an obligation to my patients to advocate for them, and I have a desire to participate as many of my colleagues and friends have, he said. We all know that 2020 has been a challenging year, and while I have not yet gone to a public protest, I have not ruled it out.

The question of whether or not to send children of any age back to school right now was especially hard for most of our experts. This week, Cooper is expected to announce the states plan for reopening schools, but many parents are conflicted.

There is a terrible tension between the concerns regarding infection at school and the emotional and educational well-being of children and their families, said Wohl, who noted that the American Academy of Pediatrics recommended that students be physically present in school provided transmission mitigating strategies are also in place.

They point out the toll being out of school is taking on children and adolescents, as well as their parents and caregivers, he said. I do think a balance can be arrived at.

When it comes to college students returning to campus, Wohl says that is more challenging when the student resides on campus, rather than at home. This requires a lot of discussion for all those impacted by campus reopening, and a close eye on regional trends related to the pandemic.

Permar, our expert in pediatric infectious disease and immunology, has school-age children and says she will send them back to school.

I support in-person school for all of the benefits that children receive there, including teacher and peer interactions, physical activity and stable meals, that I believe outweighs the risks for children, she said. The limited disease from SARS-CoV-2 infection in children has been consistent. Moreover, there is growing data that children are less likely to transmit to adults versus the other way around, and masking would further reduce transmission.

Permar says that masking teachers and staff and eliminating unmasked interactions with co-workers (for example, no eating together) should provide them protection. This has proven effective in protecting health care workers, she said.

But she stresses that resources must be committed to schools to make sure they have personal protective equipment for staff, adequate cleaning supplies and the ability to physically distance everyone.

We should prioritize opening schools over other parts of society, such as restaurants and bars, and promote the development of harm-reduction metrics to monitor virus transmission and child well-being that are specific to school settings instead of applying measures of adult case numbers only to determine if the benefits continue to outweigh the risks of keeping schools open, Permar said.

Kippes agrees, saying he would send his children back to school or college as long as they have plans that follow recommended guidelines including procedures for social distancing.

Barzin, who has a toddler, recognizes the need for school kids to have social interaction, but isnt sure whats best right now.

Its a really tough decision as a family, he said. Its hard because you really want to promote the educational component and the social interaction, but if youre 6 years old and youre doing that in a separated space, how much benefit is actually there for the child versus the instruction that theyre getting? Its really tough to know.

Moody is perhaps most cautious.

This is challenging, he said. While most data suggests the young are at less risk, its not zero risk. And large gatherings like school are the perfect way to transmit an illness like COVID-19.

That being said, there are very good reasons to send children to school and college, including their education and the social interaction they get.

Moody also recognizes that many parents depend on school so that they can go to work, so there are economic impacts, too.

I dont think this is something that has a single right answer, but I think some degree of caution is needed, he said.

Even with what Moody considers reasonable college plans, which have students on campus without breaks and finishing before Thanksgiving, its hard to prevent the students from interacting with the outside world. And once the virus gets into the student population, it may be hard to control, he added.

As of right now, Im adopting a wait-and-see attitude, and I think we are probably in for some combination of home schooling, smaller classes, and altered schedules for a while to come.

Read more here:
Is it safe to send kids to school? Visit gyms? Attend a protest? N.C. experts weigh in. - Greensboro News & Record

Read More...

Is it safe to send kids to school? Visit gyms? Attend a protest? N.C. experts weigh in. – Winston-Salem Journal

Saturday, July 11th, 2020

RALEIGH As North Carolina prepared to enter Phase Two of Gov. Roy Cooper's plan to reopen the state in the midst of the coronavirus pandemic, we talked to some local health experts in May about which Phase Two activities they considered safe or risky.

We asked doctors from UNC and Duke at that time about their comfort level in visiting restaurant dining rooms, barbershops and nail salons, swimming pools, malls and indoor church services.

For this follow-up two months later, we asked our experts how they felt about sending kids (or young adults) back to school in the fall; about patronizing bars, gyms and bowling alleys; and about attending outdoor protests.

The first thing we learned from checking back in with our experts is that their feelings about the activities we discussed in our first story haven't changed much. In fact, if anything, most of our doctors held stricter opinions now than they did in May.

On Saturday, North Carolina had nearly 1,100 people in hospitals with COVID-19 issues, marking the fifth consecutive day the state broke a record for hospitalizations, according to data from the N.C. Department of Health and Human Services. There were 1,093 hospitalizations on Saturday and the number of positive confirmed cases of coronavirus hit an all-time, one-day high of 2,462 since the virus reached the state in early March.

"Compared to May, the risk of being infected with this coronavirus has only increased," said Dr. David Alain Wohl, a professor at the Institute of Global Health and Infectious Diseases at UNC-Chapel Hill.

"There are more people infected currently out and about, and many are not mask-wearing or physically distancing either, for reasons that are not evidence-based or because they are being neglectful."

Dr. Amir Barzin, professor and director of UNC Family Medicine Center, has also become more cautious since May.

"A lot of what we talked about before still is very applicable to right now," Barzin said. "If anything, I'm understanding as a physician that this is a longer and longer course, and so my ethical responsibility as a doctor is to try to keep myself healthy and safe longer and longer. So if anything, maybe I've become a bit more conservative."

In addition to Wohl and Barzin, we followed up with Dr. Tony Moody, associate professor in the Department of Pediatrics at Duke University School of Medicine and member of the Duke Human Vaccine Institute; and Dr. Sallie Permar, a professor of pediatric infectious disease, immunology and molecular genetics at the Duke School of Medicine. In our first round, we also spoke to Regina Petteway, director of Wake County Human Services. Petteway retired on July 1, so for our follow-up, we talked to Chris Kippes, Wake County Public Health division director.

There has been much discussion about reopening bars and gyms, so we asked our experts if those are places they would feel comfortable visiting.

For our experts, it's a resounding "no" particularly in regard to bars.

Wohl told us "no way" when we asked about bars, and "absolutely not" when we asked about gyms. As for exercise, "I exercise out of doors with others who I stay a generous distance from," Wohl said.

Moody was also a "no" on bars and gyms.

"While I really like the socialization, the bar setting is exactly the kind of place where transmission may be easiest," Moody said. "People may have lowered inhibitions, and they are usually in tight quarters, often talking directly into each other's faces or ears, especially if conversation and music is loud."

Moody said that like bars, the activities in gyms are exactly those most likely to speed transmission.

"People are breathing heavily and may be much less likely to wear a mask, both of which would facilitate virus spread into the air," Moody said.

"Also, people may be touching their face more frequently and then depositing infectious particles on surfaces, and it is challenging to have people be scrupulous about cleaning surfaces after every use. Classes (spin, yoga, aerobics, etc.) where you have many people in a tight space are perfect for transmission."

Moody says for now he is working out at home and getting lots of outdoor exercise by biking and walking, making sure he can distance and avoid people.

"Even then," he added, "I've taken to carrying a mask so that if I have to approach someone, I can cover up."

Barzin told us that he would "definitely not" visit a bar right now.

"That is one of the absolute 'hard Nos' for me," he said, citing an atmosphere favorable to the "potential spread of contagion."

Barzin said he understands bar owners' desire to reopen, but worries about the long-term repercussions of opening too soon and then having an outbreak associated with a business.

But he said there is, in theory, a right way and a wrong way to reopen.

"If you have the opportunity to be outdoors, if you put tables outdoors, that would make it more attractive, I think," Barzin said. "It makes it more safe for the patrons. But right now, I'm trying to limit exposure in confined areas for prolonged periods of time. "

His feelings about gyms are similar.

"I think again this is one of those situations where you get a lot of people confined," he said. "Especially in a gym, people are exerting themselves, they are breathing harder ... that is not an area where I'd spend a lot of time."

Permar is in agreement about bars and gyms.

"The point of going to a bar, congregating and talking in a group of adults, is a high-risk setting for transmission," she said. "Moreover, drinking and universal masking don't mix well. But I would like to be able to order takeout cocktails!"

At gyms, the heavy breathing during a workout can be a high-risk setting for transmission, Permar said.

"And masking could be seen as a challenge and may be less effective in this setting. Outdoor, spaced group workouts seem like a way for group physical activity to continue."

Kippes said he would not visit a bar at this time. He said he would visit a gym "only if the gym was able to assure social distancing, require use of face masks/coverings and have procedures in place to keep equipment clean between individual usage."

The reason we asked this question which on the surface may seem a little random is because of the recent lawsuit in which owners of bowling alleys are demanding they be allowed to reopen. This week, Wake County Superior Court Judge James Gale said Gov. Roy Cooper didn't give good enough evidence why bowling alleys should remain closed.

Our health experts disagree.

Moody said he would "probably not" go bowling for some of the same reasons he wouldn't go to a bar or gym.

"Bowling alleys are generally less crowded and the exertion level is lower, but the enclosed space is still an issue," he said.

Permar said she will avoid this type of indoor activity because it promotes a congregation of adults. (She is very hopeful that drive-in movies will make a comeback, though.)

Barzin also dislikes the idea of "a lot of people in one area at the same time."

Bowling is "not something we do on a regular basis and not something we would start doing at this time," he said.

Kippes says if the bowling alley was able to assure social distancing and require the use of face coverings, he would consider it.

Wohl was straight and to the point: "No offense to bowling fans, but this seems like a really low priority during an ongoing pandemic."

Our experts were a little more mixed in their comfort level attending protests, but primarily agreed that it all depends on the circumstances.

Wohl warned against any mass gatherings, including protests, sporting events or political rallies, where masks are eschewed and people are packed closely together. These types of situations "smack of a denial that there is a deadly contagious pathogen circulating in our country," he said.

And when you take those activities indoors, even worse, he said.

But if mask rules and distancing protocols are followed, and it takes place outdoors, Wohl is more comfortable with protests.

"Demonstrations organized to promote distancing and face masks and are held in the open air, are less risky," he said. "And given the importance of such protests at this moment, (they) are acceptable to me."

Kippes said he would attend an outdoor protest or rally if social distancing was maintained and all who attended wore face masks or coverings.

Permar said she is not only comfortable with attending outdoor protests, she has done it.

"I would and have (attend a protest), while wearing a mask and distancing," she said. "I support the important fight against systemic racism which has been amplified by these protests over the last few weeks."

Barzin said he supports protests, and feels that the ones where people are spaced and wearing face coverings are "a little bit safer in terms of something I would consider doing."

"If it was a large mass protest where they weren't requiring those things, even though I would feel like the social issues are the correct ones to participate in, I don't know if I would be out there participating in that just based off the fact that my job requires me to be healthy. I want to provide good care for people, I don't want to put any extra risk on myself or my family or my patients."

Moody was conflicted about protests, but echoed Barzin's concerns about putting his patients at risk.

"Being outdoors is helpful, the crowds are not," he said. "I am very supportive of our right as Americans to protest and view the choice to do so, even at a time of pandemic, as intensely personal."

Moody said he has considered attending protests in Raleigh, but in the end opted not to because he feels an obligation to his patients to be well when he sees them.

"However, I also have an obligation to my patients to advocate for them, and I have a desire to participate as many of my colleagues and friends have," he said. "We all know that 2020 has been a challenging year, and while I have not yet gone to a public protest, I have not ruled it out."

The question of whether or not to send children of any age back to school right now was especially hard for most of our experts. Next week, Cooper is expected to announce the state's plan for reopening schools, but many parents are conflicted.

"There is a terrible tension between the concerns regarding infection at school and the emotional and educational well-being of children and their families," said Wohl, who noted that the American Academy of Pediatrics recommended that students be physically present in school provided "transmission mitigating strategies" are also in place.

"They point out the toll being out of school is taking on children and adolescents, as well as their parents and caregivers," he said. "I do think a balance can be arrived at."

When it comes to college students returning to campus, Wohl says that is "more challenging when the student resides on campus, rather than at home. This requires a lot of discussion for all those impacted by campus reopening, and a close eye on regional trends related to the pandemic."

Permar, our expert in pediatric infectious disease and immunology, has school-age children and says she will send them back to school.

"I support in-person school for all of the benefits that children receive there, including teacher and peer interactions, physical activity and stable meals, that I believe outweighs the risks for children," she said. "The limited disease from SARS-CoV-2 infection in children has been consistent. Moreover, there is growing data that children are less likely to transmit to adults versus the other way around, and masking would further reduce transmission."

Permar says that masking teachers and staff and eliminating unmasked interactions with co-workers (for example, no eating together) should provide them protection. This has proven effective in protecting health care workers, she said.

But she stresses that resources must be committed to schools to make sure they have personal protective equipment for staff, adequate cleaning supplies and the ability to physically distance everyone.

"We should prioritize opening schools over other parts of society, such as restaurants and bars, and promote the development of harm-reduction metrics to monitor virus transmission and child well-being that are specific to school settings instead of applying measures of adult case numbers only to determine if the benefits continue to outweigh the risks of keeping schools open," Permar said.

Kippes agrees, saying he would send his children back to school or college as long as they have plans that "follow recommended guidelines including procedures for social distancing."

Barzin, who has a toddler, recognizes the need for school kids to have social interaction, but isn't sure what's best right now.

"It's a really tough decision as a family," he said. "It's hard because you really want to promote the educational component and the social interaction, but if you're 6 years old and you're doing that in a separated space, how much benefit is actually there for the child versus the instruction that they're getting? It's really tough to know."

Moody is perhaps most cautious.

"This is challenging," he said. "While most data suggests the young are at less risk, it's not zero risk. And large gatherings like school are the perfect way to transmit an illness like COVID-19.

"That being said, there are very good reasons to send children to school and college, including their education and the social interaction they get."

Moody also recognizes that many parents depend on school so that they can go to work, so there are economic impacts, too.

"I don't think this is something that has a single right answer, but I think some degree of caution is needed," he said.

Even with what Moody considers "reasonable" college plans, which have students on campus without breaks and finishing before Thanksgiving, it's hard to prevent the students from interacting with the outside world.

"And once the virus gets into the student population, it may be hard to control," he added.

"As of right now, I'm adopting a wait-and-see attitude, and I think we are probably in for some combination of home schooling, smaller classes, and altered schedules for a while to come."

Go here to read the rest:
Is it safe to send kids to school? Visit gyms? Attend a protest? N.C. experts weigh in. - Winston-Salem Journal

Read More...

Global Direct-to-Consumer (DTC) Genetic Testing Industry – GlobeNewswire

Saturday, July 11th, 2020

New York, July 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Direct-to-Consumer (DTC) Genetic Testing Industry" - https://www.reportlinker.com/p05442614/?utm_source=GNW 2 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 18.5% over the analysis period 2020-2027.Ancestry & Relationship Testing, one of the segments analyzed in the report, is projected to grow at a 18.4% CAGR to reach US$1.6 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Carrier Testing segment is readjusted to a revised 19% CAGR for the next 7-year period. This segment currently accounts for a 20% share of the global Direct-to-Consumer (DTC) Genetic Testing market.

The U.S. Accounts for Over 26.9% of Global Market Size in 2020, While China is Forecast to Grow at a 23.9% CAGR for the Period of 2020-2027 The Direct-to-Consumer (DTC) Genetic Testing market in the U.S. is estimated at US$310.1 Million in the year 2020. The country currently accounts for a 26.9% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$900.9 Million in the year 2027 trailing a CAGR of 23.7% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.2% and 16.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR while Rest of European market (as defined in the study) will reach US$900.9 Million by the year 2027.

Predictive Testing Segment Corners a 15.5% Share in 2020 In the global Predictive Testing segment, USA, Canada, Japan, China and Europe will drive the 21.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$133.8 Million in the year 2020 will reach a projected size of US$528.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$599.6 Million by the year 2027, while Latin America will expand at a 25% CAGR through the analysis period. We bring years of research experience to this 17th edition of our report. The 327-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

-Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05442614/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Genetic Testing: A Synopsis Recent Market Activity Direct-to-Consumer (DTC) Genetic Testing: An Overview Major Factors Impacting DTC Genetic Testing Market Regulatory Restrictions and Privacy Concerns - Major Dampeners for DTC Genetic Testing Consumers Self-Managing Treatments: The New Trend Authorities Grappling With Setting Appropriate Regulations for DTC Genetic Testing Changing Landscape of DTC Genetic Testing Regulations to Determine Market Viability Potential Benefits Outweigh Concerns DTC Genetic Testing: High Potential Benefits, But Concerns Persist Quality Assurance Confidentiality of Genetic Information Price and Related Services Greater Chances of Misinterpretation Regulatory Headwinds and Data Paucity Impacting DTC Genetic Testing Market Despite Progress in DTC Genetic Testing Regulations, Concerns Still Linger Transparency of Data: Bugbear of DTC Genetic Testing Companies The Contextual Privacy Conundrum Increasing Adoption Raises the Threat of Data Breach DTC Genetic Testing Companies - An Unregulated Lot Association for Molecular Pathology v. Myriad Genetics, Inc. Ruling Removes Potential Barriers for DTC Genetic Testing Companies Competitive Scenario Recent Transactions in DTC Genetics Testing Market Global Competitor Market Shares Direct-to-Consumer (DTC) Genetic Testing Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS 23andMe, Inc. (USA) Ancestry.com, LLC (USA) Any Lab Test Now (USA) Color Genomics, Inc. (USA) Counsyl, Inc. (USA) Direct Laboratory Services, LLC (USA) Gene by Gene, Ltd. (USA) Laboratory Corporation of America Holdings (USA) Mapmygenome India Limited (India) Positive Bioscience, Inc. (India) Quest Diagnostics, Inc. (USA) Request A Test, Ltd. (USA) Sonora Quest Laboratories LLC (USA) Xcode Life Sciences (India)

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: Direct-to-Consumer (DTC) Genetic Testing Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027

Table 2: Direct-to-Consumer (DTC) Genetic Testing Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019

Table 3: Direct-to-Consumer (DTC) Genetic Testing Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027

Table 4: Ancestry & Relationship Testing (Test Type) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 5: Ancestry & Relationship Testing (Test Type) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 6: Ancestry & Relationship Testing (Test Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

Table 7: Carrier Testing (Test Type) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027

Table 8: Carrier Testing (Test Type) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019

Table 9: Carrier Testing (Test Type) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027

Table 10: Predictive Testing (Test Type) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027

Table 11: Predictive Testing (Test Type) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019

Table 12: Predictive Testing (Test Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 13: Nutrigenomics Testing (Test Type) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020 to 2027

Table 14: Nutrigenomics Testing (Test Type) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 15: Nutrigenomics Testing (Test Type) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027

Table 16: Other Test Types (Test Type) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 17: Other Test Types (Test Type) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 18: Other Test Types (Test Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 19: Single Nucleotide Polymorphism (SNP) Chips (Technology) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020 to 2027

Table 20: Single Nucleotide Polymorphism (SNP) Chips (Technology) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 21: Single Nucleotide Polymorphism (SNP) Chips (Technology) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027

Table 22: Targeted Analysis (Technology) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2020 to 2027

Table 23: Targeted Analysis (Technology) Global Historic Demand in US$ Thousand by Region/Country: 2012 to 2019

Table 24: Targeted Analysis (Technology) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 25: Whole Genome Sequencing (WGS) (Technology) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 26: Whole Genome Sequencing (WGS) (Technology) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 27: Whole Genome Sequencing (WGS) (Technology) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Market Facts & Figures US Direct-to-Consumer (DTC) Genetic Testing Market Share (in %) by Company: 2020 & 2025 Market Analytics Table 28: United States Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Projections in US$ Thousand by Test Type: 2020 to 2027

Table 29: Direct-to-Consumer (DTC) Genetic Testing Market in the United States by Test Type: A Historic Review in US$ Thousand for 2012-2019

Table 30: United States Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Test Type: 2012 VS 2020 VS 2027

Table 31: Direct-to-Consumer (DTC) Genetic Testing Market in US$ Thousand in the United States by Technology: 2020-2027

Table 32: United States Direct-to-Consumer (DTC) Genetic Testing Market Retrospective Analysis in US$ Thousand by Technology: 2012-2019

Table 33: United States Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

CANADA Table 34: Canadian Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in US$ Thousand by Test Type: 2020 to 2027

Table 35: Canadian Direct-to-Consumer (DTC) Genetic Testing Historic Market Review by Test Type in US$ Thousand: 2012-2019

Table 36: Direct-to-Consumer (DTC) Genetic Testing Market in Canada: Percentage Share Breakdown of Sales by Test Type for 2012, 2020, and 2027

Table 37: Direct-to-Consumer (DTC) Genetic Testing Market Analysis in Canada in US$ Thousand by Technology: 2020-2027

Table 38: Direct-to-Consumer (DTC) Genetic Testing Market in Canada: Historic Review in US$ Thousand by Technology for the Period 2012-2019

Table 39: Canadian Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

JAPAN Table 40: Japanese Market for Direct-to-Consumer (DTC) Genetic Testing: Annual Sales Estimates and Projections in US$ Thousand by Test Type for the Period 2020-2027

Table 41: Direct-to-Consumer (DTC) Genetic Testing Market in Japan: Historic Sales Analysis in US$ Thousand by Test Type for the Period 2012-2019

Table 42: Japanese Direct-to-Consumer (DTC) Genetic Testing Market Share Analysis by Test Type: 2012 VS 2020 VS 2027

Table 43: Japanese Medium & Long-Term Outlook for Direct-to-Consumer (DTC) Genetic Testing Market in US$ Thousand by Technology: 2020-2027

Table 44: Direct-to-Consumer (DTC) Genetic Testing Market in Japan in US$ Thousand by Technology: 2012-2019

Table 45: Japanese Direct-to-Consumer (DTC) Genetic Testing Market Percentage Share Distribution by Technology: 2012 VS 2020 VS 2027

CHINA Table 46: Chinese Direct-to-Consumer (DTC) Genetic Testing Market Growth Prospects in US$ Thousand by Test Type for the Period 2020-2027

Table 47: Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in China in US$ Thousand by Test Type: 2012-2019

Table 48: Chinese Direct-to-Consumer (DTC) Genetic Testing Market by Test Type: Percentage Breakdown of Sales for 2012, 2020, and 2027

Table 49: Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in China in US$ Thousand by Technology: 2020-2027

Table 50: Chinese Direct-to-Consumer (DTC) Genetic Testing Retrospective Market Scenario in US$ Thousand by Technology: 2012-2019

Table 51: Direct-to-Consumer (DTC) Genetic Testing Market in China: Percentage Share Analysis by Technology for 2012, 2020, and 2027

EUROPE Market Facts & Figures European Direct-to-Consumer (DTC) Genetic Testing Market: Competitor Market Share Scenario (in %) for 2020 & 2025 Market Analytics Table 52: European Direct-to-Consumer (DTC) Genetic Testing Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027

Table 53: Direct-to-Consumer (DTC) Genetic Testing Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019

Table 54: European Direct-to-Consumer (DTC) Genetic Testing Market Share Shift by Region/Country: 2012 VS 2020 VS 2027

Table 55: European Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in US$ Thousand by Test Type: 2020-2027

Table 56: Direct-to-Consumer (DTC) Genetic Testing Market in Europe in US$ Thousand by Test Type: A Historic Review for the Period 2012-2019

Table 57: European Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Test Type: 2012 VS 2020 VS 2027

Table 58: European Direct-to-Consumer (DTC) Genetic Testing Market Assessment in US$ Thousand by Technology: 2020-2027

Table 59: European Direct-to-Consumer (DTC) Genetic Testing Historic Market Review in US$ Thousand by Technology: 2012-2019

Table 60: Direct-to-Consumer (DTC) Genetic Testing Market in Europe: Percentage Breakdown of Sales by Technology for 2012, 2020, and 2027

FRANCE Table 61: Direct-to-Consumer (DTC) Genetic Testing Market in France by Test Type: Estimates and Projections in US$ Thousand for the Period 2020-2027

Table 62: French Direct-to-Consumer (DTC) Genetic Testing Historic Market Scenario in US$ Thousand by Test Type: 2012-2019

Table 63: French Direct-to-Consumer (DTC) Genetic Testing Market Share Analysis by Test Type: 2012 VS 2020 VS 2027

Table 64: French Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Projections in US$ Thousand by Technology: 2020-2027

Table 65: French Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in US$ Thousand by Technology: 2012-2019

Table 66: French Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

GERMANY Table 67: Direct-to-Consumer (DTC) Genetic Testing Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Test Type for the Period 2020-2027

Table 68: German Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in US$ Thousand by Test Type: 2012-2019

Table 69: German Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Test Type: 2012 VS 2020 VS 2027

Table 70: German Direct-to-Consumer (DTC) Genetic Testing Latent Demand Forecasts in US$ Thousand by Technology: 2020-2027

Table 71: Direct-to-Consumer (DTC) Genetic Testing Market in Germany: A Historic Perspective by Technology in US$ Thousand for the Period 2012-2019

Table 72: German Direct-to-Consumer (DTC) Genetic Testing Market Share Breakdown by Technology: 2012 VS 2020 VS 2027

ITALY Table 73: Italian Direct-to-Consumer (DTC) Genetic Testing Market Growth Prospects in US$ Thousand by Test Type for the Period 2020-2027

Table 74: Direct-to-Consumer (DTC) Genetic Testing Historic Market Analysis in Italy in US$ Thousand by Test Type: 2012-2019

Table 75: Italian Direct-to-Consumer (DTC) Genetic Testing Market by Test Type: Percentage Breakdown of Sales for 2012, 2020, and 2027

Table 76: Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in Italy in US$ Thousand by Technology: 2020-2027

Table 77: Italian Direct-to-Consumer (DTC) Genetic Testing Retrospective Market Scenario in US$ Thousand by Technology: 2012-2019

Table 78: Direct-to-Consumer (DTC) Genetic Testing Market in Italy: Percentage Share Analysis by Technology for 2012, 2020, and 2027

UNITED KINGDOM Table 79: United Kingdom Market for Direct-to-Consumer (DTC) Genetic Testing: Annual Sales Estimates and Projections in US$ Thousand by Test Type for the Period 2020-2027

Table 80: Direct-to-Consumer (DTC) Genetic Testing Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Test Type for the Period 2012-2019

Table 81: United Kingdom Direct-to-Consumer (DTC) Genetic Testing Market Share Analysis by Test Type: 2012 VS 2020 VS 2027

Table 82: United Kingdom Medium & Long-Term Outlook for Direct-to-Consumer (DTC) Genetic Testing Market in US$ Thousand by Technology: 2020-2027

Table 83: Direct-to-Consumer (DTC) Genetic Testing Market in the United Kingdom in US$ Thousand by Technology: 2012-2019

Table 84: United Kingdom Direct-to-Consumer (DTC) Genetic Testing Market Percentage Share Distribution by Technology: 2012 VS 2020 VS 2027

SPAIN Table 85: Spanish Direct-to-Consumer (DTC) Genetic Testing Market Estimates and Forecasts in US$ Thousand by Test Type: 2020 to 2027

Table 86: Spanish Direct-to-Consumer (DTC) Genetic Testing Historic Market Review by Test Type in US$ Thousand: 2012-2019

Table 87: Direct-to-Consumer (DTC) Genetic Testing Market in Spain: Percentage Share Breakdown of Sales by Test Type for 2012, 2020, and 2027

Table 88: Direct-to-Consumer (DTC) Genetic Testing Market Analysis in Spain in US$ Thousand by Technology: 2020-2027

Read the original here:
Global Direct-to-Consumer (DTC) Genetic Testing Industry - GlobeNewswire

Read More...

Scores forecast effects of mutations in autism gene – Spectrum

Saturday, July 11th, 2020

Mutation rating: Scores may help researchers identify changes in the gene PTEN most likely to play a role in autism.

CRAFTSCI / Science Photo Library

A new analysis links individual mutations in a gene called PTEN to a persons odds of having autism, cancer or other conditions1. The findings may help clinicians and researchers predict the effects of various mutations in the gene.

PTEN controls cell growth and regulates the strength of connections between neurons. Mutations in the gene are associated with a variety of conditions, including autism, macrocephaly (enlarged head size), benign tumors and several types of cancer. It is still unclear how different mutations cause such varied effects.

Scientists cannot easily predict the consequences of a PTEN mutation based on its type whether it involves a single amino acid change or a larger interruption to the gene, for example or its impact on the protein the gene encodes. Researchers have developed methods to examine the molecular effects of PTEN mutations within cells in a dish, but these approaches do not link mutations to specific conditions in people.

In the new analysis, the researchers probed the effects of 7,657 PTEN mutations, representing all possible changes to each amino acid in the genes sequence. They built on the findings from a previous study in which they used yeast cells to calculate a fitness score for 7,244 PTEN mutations2. They combined this dataset with another in which researchers had given an abundance score to 4,112 PTEN mutations based on how those mutations affect protein levels in human cells in a dish3.

The team used machine learning on the combined dataset to calculate abundance and fitness scores for mutations that lacked them. They then compared these scores with data they gathered from 421 people with PTEN mutations 165 controls and 256 people with a PTEN-related condition, such as autism, developmental delay, intellectual disability, macrocephaly, or benign or malignant tumors.

People with the largest head size tend to have mutations with the lowest fitness and abundance scores, the researchers reported in June in the American Journal of Human Genetics. Similarly, low scores track with having PTEN-related conditions that are severe or appear at a young age.

By comparing mutations in individuals with PTEN-linked traits and those in controls, the researchers also found that fitness scores can predict whether a mutation is likely to lead to a PTEN-related condition.

Together, these findings suggest that abundance and fitness scores may help predict the consequences of PTEN mutations, the researchers say.

The team also split single amino acid changes into three classes based on the severity of their effects on protein function and abundance.

The most severe mutations are linked to a higher likelihood of cancer diagnosis by age 35 compared with the least severe mutations, the researchers found. Greater severity also tracks with an increased likelihood of tumor-like growths.

However, the severity of the variants effects is not tied to a persons likelihood of having autism or developmental delay. This suggests that even a small decrease in PTEN activity may be enough to significantly increase the odds of having a neurodevelopmental condition, the researchers say.

The analysis may help tease apart PTEN mutations different effects, the researchers say. It may also help researchers identify the mutations most likely to play a role in autism and prioritize them for further research.

Read the original post:
Scores forecast effects of mutations in autism gene - Spectrum

Read More...

Global Carrier Screening Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2027|Myriad Genetics, Inc., Pathway Genomics,…

Saturday, July 11th, 2020

Carrier screening marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account toUSD 6.47 billion by 2027 growing at a CAGR of 17.40% in the above-mentioned forecast period.

The major players covered in the carrier screening market report areF. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Illumina, Inc., QIAGEN, Myriad Genetics, Inc., Pathway Genomics, Siemens Healthcare GmbH, Genomic Health, Inc., Admera Health, deCODE geneticsamong other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa(MEA) and South America separately. DBMR analystsunderstand competitive strengths and provide competitive analysis for each competitor separately.

Access Sample Copy Of Carrier Screening Market @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-carrier-screening-market

This Carrier Screening research report provides introduction to the market including current market size estimates, market splits by vendors, end user segments and by region. Market trends, Market dynamics and Market Restraints.

Geographically this Carrier Screening research report divides the market in the global regions like North America, South America, Asia and Pacific region, Middle east and Africa and Europe.

Key benefits of the report

The global Carrier screening market is also presented to the readers as a holistic snapshot of the competitive landscape within the given forecast period. The report also educates about the market strategies that are being adopted by your competitors and leading organizations. The report also focuses on all the recent industry trends. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of where areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the market.

To register for digital conference click here @https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Global Carrier Screening Market:Segmentation

Carrier screening market is segmented onthe basis of test type, disease type, medical condition, technology and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on test type, carrier screening market is segmented into molecular screening test, and biochemical screening test.

On the basis of disease type, thecarrier screening marketis segmented into cystic fibrosis, tay-sachs, gaucher disease, sickle cell disease, spinal muscular atrophy, and other autosomal recessive genetic disorders.

On the basis of medical condition, the carrier screening market is segmented into pulmonary conditions, hematological conditions, neurological conditions, and others.

On the basis of technology, the carrier screening market is segmented into DNA sequencing, polymerase chain reaction, microarrays, and others.

Carrier screening markethas also been segmented based onthe end use into hospitals, reference laboratories, physician offices & clinics, and others.

Table Of Content:

Part 01: Executive SummaryPart 02: Scope Of The ReportPart 03: Global carrier screening Market Landscape

Part 04: Global carrier screening Market Sizing

Part 05: Global carrier screening Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer LandscapePart 08: Geographic Landscape

Part 09: Decision FrameworkPart 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Get Detailed Table Of[emailprotected]https://www.databridgemarketresearch.com/toc/?dbmr=global-carrier-screening-market

About Us:Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Go here to read the rest:
Global Carrier Screening Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2027|Myriad Genetics, Inc., Pathway Genomics,...

Read More...

New Report: Expression Vectors Market Segmentation Along With Regional Outlook, Competitive Strategies, Factors Contributing To Growth 2020-2026|,…

Saturday, July 11th, 2020

LOS ANGELES, United States: QY Research has recently published a report, titled Global Expression Vectors Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Expression Vectors market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Expression Vectors market include: , Promega, Agilent, Thermo Fisher, Bio-Rad, Merck Millipore, QIAGEN, Takara Bio, ATUM, New England Biolabs, Sigma-Aldrich, GenScript

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1527811/global-expression-vectors-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Expression Vectors market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Expression Vectors Market Segment By Type:

BacterialMammalianYeastInsect Expression Vectors

Global Expression Vectors Market Segment By Application:

GeneticsMolecular biologyBioinformaticsUnmet medical needs Based on

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Expression Vectors market.

Key companies operating in the global Expression Vectors market include , Promega, Agilent, Thermo Fisher, Bio-Rad, Merck Millipore, QIAGEN, Takara Bio, ATUM, New England Biolabs, Sigma-Aldrich, GenScript

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1527811/global-expression-vectors-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Expression Vectors Market Size Growth Rate by Type: 2020 VS 20261.2.2 Bacterial1.2.3 Mammalian1.2.4 Yeast1.2.5 Insect1.3 Market by Application1.3.1 Global Expression Vectors Market Share by Application: 2020 VS 20261.3.2 Genetics1.3.3 Molecular biology1.3.4 Bioinformatics1.3.5 Unmet medical needs 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends2.1 Global Expression Vectors Market Perspective (2015-2026)2.2 Global Expression Vectors Growth Trends by Regions2.2.1 Expression Vectors Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Expression Vectors Historic Market Share by Regions (2015-2020)2.2.3 Expression Vectors Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Expression Vectors Players by Market Size3.1.1 Global Top Expression Vectors Players by Revenue (2015-2020)3.1.2 Global Expression Vectors Revenue Market Share by Players (2015-2020)3.2 Global Expression Vectors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Expression Vectors Revenue3.4 Global Expression Vectors Market Concentration Ratio3.4.1 Global Expression Vectors Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Expression Vectors Revenue in 20193.5 Key Players Expression Vectors Area Served3.6 Key Players Expression Vectors Product Solution and Service3.7 Date of Enter into Expression Vectors Market3.8 Mergers & Acquisitions, Expansion Plans 4 Expression Vectors Breakdown Data by Type (2015-2026)4.1 Global Expression Vectors Historic Market Size by Type (2015-2020)4.2 Global Expression Vectors Forecasted Market Size by Type (2021-2026) 5 Expression Vectors Breakdown Data by Application (2015-2026)5.1 Global Expression Vectors Historic Market Size by Application (2015-2020)5.2 Global Expression Vectors Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Expression Vectors Market Size (2015-2026)6.2 North America Expression Vectors Market Size by Type (2015-2020)6.3 North America Expression Vectors Market Size by Application (2015-2020)6.4 North America Expression Vectors Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Expression Vectors Market Size (2015-2026)7.2 Europe Expression Vectors Market Size by Type (2015-2020)7.3 Europe Expression Vectors Market Size by Application (2015-2020)7.4 Europe Expression Vectors Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Expression Vectors Market Size (2015-2026)8.2 China Expression Vectors Market Size by Type (2015-2020)8.3 China Expression Vectors Market Size by Application (2015-2020)8.4 China Expression Vectors Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Expression Vectors Market Size (2015-2026)9.2 Japan Expression Vectors Market Size by Type (2015-2020)9.3 Japan Expression Vectors Market Size by Application (2015-2020)9.4 Japan Expression Vectors Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia Expression Vectors Market Size (2015-2026)10.2 Southeast Asia Expression Vectors Market Size by Type (2015-2020)10.3 Southeast Asia Expression Vectors Market Size by Application (2015-2020)10.4 Southeast Asia Expression Vectors Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11Key Players Profiles11.1 Promega11.1.1 Promega Company Details11.1.2 Promega Business Overview11.1.3 Promega Expression Vectors Introduction11.1.4 Promega Revenue in Expression Vectors Business (2015-2020))11.1.5 Promega Recent Development11.2 Agilent11.2.1 Agilent Company Details11.2.2 Agilent Business Overview11.2.3 Agilent Expression Vectors Introduction11.2.4 Agilent Revenue in Expression Vectors Business (2015-2020)11.2.5 Agilent Recent Development11.3 Thermo Fisher11.3.1 Thermo Fisher Company Details11.3.2 Thermo Fisher Business Overview11.3.3 Thermo Fisher Expression Vectors Introduction11.3.4 Thermo Fisher Revenue in Expression Vectors Business (2015-2020)11.3.5 Thermo Fisher Recent Development11.4 Bio-Rad11.4.1 Bio-Rad Company Details11.4.2 Bio-Rad Business Overview11.4.3 Bio-Rad Expression Vectors Introduction11.4.4 Bio-Rad Revenue in Expression Vectors Business (2015-2020)11.4.5 Bio-Rad Recent Development11.5 Merck Millipore11.5.1 Merck Millipore Company Details11.5.2 Merck Millipore Business Overview11.5.3 Merck Millipore Expression Vectors Introduction11.5.4 Merck Millipore Revenue in Expression Vectors Business (2015-2020)11.5.5 Merck Millipore Recent Development11.6 QIAGEN11.6.1 QIAGEN Company Details11.6.2 QIAGEN Business Overview11.6.3 QIAGEN Expression Vectors Introduction11.6.4 QIAGEN Revenue in Expression Vectors Business (2015-2020)11.6.5 QIAGEN Recent Development11.7 Takara Bio11.7.1 Takara Bio Company Details11.7.2 Takara Bio Business Overview11.7.3 Takara Bio Expression Vectors Introduction11.7.4 Takara Bio Revenue in Expression Vectors Business (2015-2020)11.7.5 Takara Bio Recent Development11.8 ATUM11.8.1 ATUM Company Details11.8.2 ATUM Business Overview11.8.3 ATUM Expression Vectors Introduction11.8.4 ATUM Revenue in Expression Vectors Business (2015-2020)11.8.5 ATUM Recent Development11.9 New England Biolabs11.9.1 New England Biolabs Company Details11.9.2 New England Biolabs Business Overview11.9.3 New England Biolabs Expression Vectors Introduction11.9.4 New England Biolabs Revenue in Expression Vectors Business (2015-2020)11.9.5 New England Biolabs Recent Development11.10 Sigma-Aldrich11.10.1 Sigma-Aldrich Company Details11.10.2 Sigma-Aldrich Business Overview11.10.3 Sigma-Aldrich Expression Vectors Introduction11.10.4 Sigma-Aldrich Revenue in Expression Vectors Business (2015-2020)11.10.5 Sigma-Aldrich Recent Development11.11 GenScript10.11.1 GenScript Company Details10.11.2 GenScript Business Overview10.11.3 GenScript Expression Vectors Introduction10.11.4 GenScript Revenue in Expression Vectors Business (2015-2020)10.11.5 GenScript Recent Development 12Analysts Viewpoints/Conclusions 13Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

More:
New Report: Expression Vectors Market Segmentation Along With Regional Outlook, Competitive Strategies, Factors Contributing To Growth 2020-2026|,...

Read More...

Researcher shares love of science with students in Greece – HSPH News

Friday, July 10th, 2020

July 10, 2020 When Eva Tsaousidou was in high school, she read something in the newspaper that changed her lifean account of how scientists in Scotland cloned the first-ever mammal, Dolly the sheep.

This was so fascinating to me, recalled Tsaousidou, a postdoctoral fellow in the Department of Molecular Metabolism at Harvard T.H. Chan School of Public Health. It made me want to be part of creating new knowledge in genetics.

Tsaousidou recently told the story about Dolly to a group of high school students in Greece, her home country, through a platform called 100 Mentors that connects scientists virtually to students all over the world. She created a profile on the platform in late 2019 and, in early 2020, got a request from Othisi High School in Athens to talk to groups of students.

In online lectures in February and March this year, Tsaousidou told the students about her research into the connections between obesity, metabolism, and cancer. They found it fascinating, said Tsaousidou. They never thought those two things could overlap. But I told them that in biology and in life, everything is connected, like rings of a chain, and if somehow one thing breaks or doesnt work well, another thing can be affected.

Tsaousidou said the students were excited to learn about her work, and the schools newspaper profiled her in June.

The students dont have a lot of examples of scientists in their life, so they had lots of big questions, she said. One of their questions surprised herthey asked if scientists were able to create human babies in the lab.

I was like, OK, guysno! she said. I told them that wasnt ethical and that scientists have strict regulations.

She was also candid with the students about the demands of the job. The working hours arent 9 to 5, she said, but I told them its very exciting, and every day there is something new and different. And you get a chance to work on things no one has worked on before.

Karen Feldscher

photo: Kent Dayton

See the original post here:
Researcher shares love of science with students in Greece - HSPH News

Read More...

With two research papers published, UW Oshkosh biologist has a whale of a week – UW Oshkosh Today

Friday, July 10th, 2020

July is off to a good start academically speaking for Morgan Churchill, an assistant biology professor at the University of Wisconsin Oshkosh.

The vertebrate paleontologist is an author on not one but two research papers published this week in high-impact, peer-reviewed journals.

First, a paper that describes a new type of giant predatory dolphin fossil appeared Thursday in Current Biology, a biweekly scientific journal that emphasizes research on molecular biology, cell biology, genetics, neurobiology, ecology and evolutionary biology.

Second, a study that examined 172 toothed whale skulls to quantify cranial asymmetry and reconstruct the evolutionary history of the aquatic mammal was published today in BMC Biology, an open access journal featuring outstanding research in all areas of biology.

Ive never had this type of week before, said Churchill, who has taught undergraduate human anatomy at UWO since joining the biology faculty in 2017.

Both studies contribute to the understanding of whale and dolphin evolution, two closely related marine mammals. In fact, all dolphins are whales but not all whales are dolphins.

Whales capture our attention as they are very intelligent and have become the poster children for environmental causes and endangered species, he said. Whales also have an excellent fossil record, making them icons of evolution.

Churchills overall research program focuses on examining how marine mammal morphology has adapted to an aquatic lifestyle over time and how changes in morphology have influenced diversity and evolution in the group. Morphology is the study of size, shape and structure of animals, plants and microorganisms.

In the Current Biology article, Churchill and colleagues at the College of Charleston, New York Institute of Technology and Wellesley College report the nearly complete skeleton of the extinct large dolphin, Ankylorhiza tiedemani, from South Carolina.

This new specimen fills in important anatomical information on the early evolution of locomotion in whales, as well as reveals the ecological diversity in whales that was already present 24 million years ago, Churchill said.

As second author on the study, Churchill carried out the anatomical analyses and collaborated on interpreting the results and writing the paper.

Ankylorhiza is not a member of any group of whales living today but rather is closely related to the common ancestor of all toothed whales.

Evidence from its anatomy suggests it was an apex predator, perhaps filling a niche today occupied by the killer whale, Orcinus orca, Churchill said.

Ankylorhiza preserves a relatively primitive vertebral column and flipper, indicating that simplification of limbs and vertebrae evolved independently in baleen whales (also known as whalebone whales) and toothed whales.

The most important finding of this study is that we provide evidence that adaptations for underwater locomotion evolved separately in these two major groups of whales alive todaybaleen whales and toothed whaleslikely due to similar functional demands, Churchill said. This highlights an excellent example of convergent evolution, as well as reveals that whale evolution is much more complicated than we thought.

In addition, this new specimen shows that even early in their evolution, toothed whales showed a high degree of diversity with different species adapting to different lifestyles and diets, he said.

Toothed whales also have some of the most bizarre skulls of any mammal group, Churchill said.

Much of this weirdness is due to the high levels of bilateral cranial asymmetry present in the skull, he explained. In most animals, the bones that make up the face are the same size for both the right and the left halves of the skull. However, in many whales, bones on the right side of the face are much larger than those on the left.

Although remarkable, the feature has been poorly studied and not rigorously quantified in fossil whales.

For the study reported in the BMC Biology article, Churchill was part of a team of researchers led by Ellen Coombs from University College London and the Natural History Museum in London.

For his part, Churchill provided a large number of 3D scans of the whales collected from museums during a post-doctoral project.

The research showed that the cranial asymmetry is likely due to development of echolocationthe ability to locate objects by reflected soundin the toothed whales.

This research highlights a major evolutionary change in one of the best examples of evolution, Churchill said. It provides the first exhaustive quantification of cranial asymmetry in whales, traces its evolution and ties the changes with asymmetry to the development of new adaptations and changes in the environment.

Churchills research lab at UWO has been a training ground for undergraduate biology students. In fall 2020, a graduate student will be joining the team.

Learn more:

Go here to see the original:
With two research papers published, UW Oshkosh biologist has a whale of a week - UW Oshkosh Today

Read More...

Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies – UCSF News Services

Friday, July 10th, 2020

Black men in the United States are known to suffer disproportionately from prostate cancer, but few studies have investigated whether genetic differences in prostate tumors could have anything to do with these health disparities.

Now, in the largest study of its kind to date, researchers from Boston University School of Medicine (BUSM), UC San Francisco (UCSF), and Northwestern University have identified genes that are more frequently altered in prostate tumors from men of African ancestry compared to other racial groups, though the reasons for these differences is not known, the authors say. None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, the authors say, as long as the therapies are applied equitably.

The newly identified gene variants could potentially lead to precision prostate cancer therapies specifically focused on men of African ancestry, and will inform broader efforts by the National Cancer Institutes RESPOND study to link gene variants to health outcomes in an even larger cohort of Black patients nationwide.

Despite declines in mortality related to cancer in the U.S., disparities by race have persisted. One in every six Black Americans will be diagnosed with prostate cancer in their lifetime, and these men are twice as likely to die from the disease as men of other races. But it is not yet clear to researchers whether differences in prostate cancer genetics contribute to these health disparities in addition to the social and environmental inequities known to drive poorer health outcomes across the board.

To date, studies trying to figure out what genes are commonly mutated in prostate cancers often have had very few samples from racial/ethnic minority groups despite the greater burden of prostate cancer in these populations. In May, the FDA approved a class of drugs known as PARP inhibitors as a therapy for men with prostate cancers driven by specific genetic mutations, but it is not known how prevalent these mutations are in people of African descent. As more genetic health studies are performed in minority populations, it has become clear that other genetically targeted therapies that have been developed based on studies of patients of European descent are at times much less effective, and in some cases cause dangerous side-effects, in other racial and ethnic groups.

In the new study, published July 10, 2020 in Clinical Cancer Research, a journal of the American Association for Cancer Research, the research team set out to better understand differences in the mutations driving prostate cancer tumors in men with African versus European ancestry, and whether any such differences could influence disease outcomes or the effectiveness of PARP inhibitors or other targeted therapies.

The researchers collected and analyzed DNA sequencing data from previously published studies and from a commercial molecular diagnostics company. In total, they examined mutational patterns in prostate cancers from more than 600 Black men, representing the largest such study of this population to date.

The team found that the frequency of mutations in DNA repair genes and other genes that are targets of current therapeutics are similar between the two groups, suggesting that at least these classes of current precision prostate cancer therapies should be beneficial in people of both African and European ancestry, according to corresponding author Franklin Huang, MD, PhD, an assistant professor in UCSFs Division of Hematology/Oncology and member of the UCSF Helen Diller Family Comprehensive Cancer Center, UCSF Institute for Human Genetics, and UCSF Bakar Computational Health Sciences Institute.

While the researchers found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, they did identify other genes, such as ZFXH3, MYC, and ETV3, that were more frequently mutated in prostate cancers from Black men.

"These results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups and that samples from Black Americans need to be included in future molecular studies to fully understand these differences," said co-corresponding author Joshua Campbell, PhD, assistant professor of medicine at BUSM.

The poorer health outcomes we see in Black men with prostate cancer are not easily explained by any of the distinct gene mutations we identified in prostate tumors from men of African ancestry. This highlights the need to examine the environmental and social inequities that are well known to influence health outcomes across the board, Huang added. On the other hand, our tumor genomic analysis also showed that current precision medicine approaches ought to be as effective in Black Americans as they have been for other groups if we can ensure that these drugs are applied equitably going forward."

Developing a comprehensive understanding of how tumor genomics and other biological factors interact with social and environmental inequities to drive poorer clinical outcomes for Black prostate cancer patients should be an important priority for the efforts to improve precision medicine for these patients, the researchers say.

These types of studies will remain important to understand when certain therapies may preferentially benefit Black patients, who continue to remain underrepresented in clinical trials, Campbell said.

In particular, the results will inform the efforts of the NCI-funded RESPOND Study. RESPOND provided funding for the new UCSF-BUSM-Northwestern study to guide its efforts to perform targeted gene sequencing in tumors from an even larger cohort of Black prostate cancer patients, said Huang, who leads RESPONDs tumor genetics studies based at UCSF. Through partnerships with Black communities across the country, RESPOND aims to recruit 10,000 Black prostate cancer patients in an effort to better understand the drivers of the diseases outsize burden among Black Americans.

"Previous studies have looked in isolation at different biological, social and environmental drivers ofwell-knownracial disparities in prostate cancer,Huangsaid. RESPOND is a nationwide effort to integrate all these components and ultimately identify specific steps that can be taken toeliminateprostate cancers unequal burden in Black communities.

Authors: The studys lead authors are Yusuke Koga of BUSM, Hanbing Song of UCSF, and Zachary Chalmers of Northwestern University. Additional authors are Elad Ziv of UCSF; Justin Newberg and Garrett M. Frampton of Foundation Medicine, in Cambridge; Eejung Kim and Daphnee Piou of the Broad Institute of MIT and Harvard; Jian Carrot-Zhang and Matthew Meyerson of the Broad Institute and Dana-Farber Cancer Institute; Paz Polak of Mt. Sinai School of Medicine in New York; and Sarki Abdulkadir of Northwestern University.

Funding: The study was supported by the U.S. Department of Defense (W81XWH-17-PCRP-HD); the U.S. National Institutes of Health (NIH) National Cancer Institute (NCI) (P20 CA233255-01, U19 CA214253); and the Prostate Cancer Foundation.

Disclosures: The authors declare no relevant conflicting financial interests.

About UCSF:The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwidethrough advanced biomedical research, graduate-level education in the life sciences and healthprofessions, and excellence in patient care. It includes UCSF Health, which comprises three top-ranked hospitals, as well as affiliations throughout the Bay Area.

About BUSM: Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine (BUSM) today is a leading academic medical center with an enrollment of more than 700 medical students and 950 students pursuing degrees in graduate medical sciences.BUSM faculty contribute to more than 950 active grants and contracts, with total anticipated awards valued at more than $693 million in amyloidosis, arthritis, cardiovascular disease, cancer, infectious diseases, pulmonary disease and dermatology, among other areas. The Schools teaching affiliates include Boston Medical Center, its primary teaching hospital, the Boston VA Healthcare System, Kaiser Permanente in northern California, as well as Boston HealthNet, a network of 15 community health centers. For more information, please visithttp://www.BUSM.bu.edu/busm/.

Go here to read the rest:
Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies - UCSF News Services

Read More...

Growing Demand for Orf Expression Clones Market to Significantly Increase Revenues Through 2025 – 3rd Watch News

Friday, July 10th, 2020

DNA is transcribe into messenger RNA, messenger RNA is translated into protein ORF. During translation, the combination of three nucleotide codons are required for protein synthesis. The nucleotide that starts translation and stops translation is known as ORF. Every DNA has six open reading frame and it is important to determine the correct open reading frame so that the protein is expressed properly. An Open Reading Frame starts with ATG (Met), which is known as start codon and ends with DNA sequence such as TAA, TAG, TGA known as stop codon. ORF clones are eliminates the wearisomesteps of RNA isolation, DNA synthesis, PCR amplification and other tedious sequencing and validation procedures.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/19597

The ORF expression clones are plasmid that contains protein coding DNA, the DNA contains the coding sequence without 5 and 3 end untranslated regions. The ORF expression clones helps to save as it moves directly protein expression and protein analysis. The ORF clones aids to get protein expression and analysis faster. The ORF allows to get gene of interest and expressed protein quickly, and help researchers to conduct clinical and medical applications. Clinical laboratory are highly equipped with assay and instrument systems used for the detection and classification of various disease type such as cancer and risk of cancer progressions, cardiovascular diseases, and others. The advancement in the molecular genetics, bioinformatics, proteomics, increasing number of infection rate is prompting manufacturers to seek newer methods of research, has led to the revenue growth over the forecast period.

Increased demand for research and development for early detection and diagnosis of disease, increased expenditure on healthcare sector, growing number of hospitals and diagnostic laboratories, increased demand for personalized medicines requires the study of individual cell structure and function, rise in prevalence of cell based diseases such as cancer and autoimmune diseases requires the detection and diagnosis of specific cell and tissue, rise in number of biopsy procedures. Technological advancement in the diagnostic and treatment process of infectious diseases, advancement in molecular techniques are the factors fueling the demand of ORF expression clone market in the near future.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/19597

The global ORF expression clones market is segmented on basis of expression system,application, end user and geography

Segment by Expression System

Segment by Application

Segment by End User

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/19597

Global ORF expression clones is segmented by expression system, application and end user. On the basis of expression system the, ORF expression clones market is segmented as mammalian expression system, lentiviral expression system, bacterial expression system, yeast expression system, insect, wheat germ cell and others. Based on the application type, global ORF expression clones market is segmented as recombinant protein expression, functional assays, protein characterization, In vitro transcription and other application for research and study purpose. On the basis of end user, the global ORF expression clones market is segmented into biotechnological companies, pharmaceutical companies, contract research organizations, academic/ research institutes. Increasing outsourcing by pharmaceutical and biotechnological companies, declining R&D productivity and patent cliff sales drop leading to increasing research intensity in the pharmaceuticals sector, rapid process/product development due to fewer steps, increased awareness about new product launch and others are some of the factors drive the global ORF expression clones market during the forecast period. Whereas high cost and short reaction scale, low protein expression, inadequate access to health care, lack of standardized tools for research and development are some of the factors that may hamper the growth of global ORF expression clones market.

By Geography, the global ORF Expression Clones market is segmented into five broad regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America is estimated to lead the global ORF expression clones market due to increasing focus on protein expression and production, growing demand for simple and efficient protein production methods, government funding for research and development in developed countries and others. Europe market is also projected to experience high growth due to emphasis on up-scaling and industrial application in the near future. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as focusing on healthcare expenditures, rise in research and development facilities and others.

Some of the major players in global ORF expression clones market are

The rest is here:
Growing Demand for Orf Expression Clones Market to Significantly Increase Revenues Through 2025 - 3rd Watch News

Read More...

"Glen Mor; the new raspberry that gives more" – hortidaily.com

Friday, July 10th, 2020

Among the three new raspberry varieties James Hutton Limited has released to soft fruit growers in 2020, Glen Mor is the floricane raspberry variety the industry has been waiting for, with genetic marker Rub118b conferring resistance to raspberry root rot, Phytophthora Rubi.

Root rot is one of the most serious raspberry diseases. Impossible to eradicate from infested soils, root rot has prompted the move to growing in pots, which are sometimes raised above the soil below as double protection from the pathogen.

Breeding for root rot resistance has long been a major objective of raspberry breeding at the James Hutton Institute. Dr Julie Graham has spent over a decade developing the first genetic linkage map for raspberry and subsequently identifying molecular markers to link important traits to genetic regions. Deployed early in the breeding process this has helped to speed the release of new varieties. Julies group identified the genetic regions significantly associated with raspberry root rot and developed a molecular marker that can be used in the James Hutton Limited breeding programme to quickly and effectively identify selections with likely resistance.

In James Hutton Institute trials, plants of Glen Mor have spent six years in a soil plot infested with root rot and have shown no symptoms of the disease, despite flooding over several seasons but, root rot resistance is not the only thing that Glen Mor has to shout about. Selected for release by the 2014-2019 tranche of the James Hutton Limited Raspberry Breeding Consortium; a partnership of marketing and grower groups, propagators, AHDB and Scottish Government, that funds the breeding programme to create new, targeted raspberry varieties, Glen Mor has been fast tracked from the breeding programme due to both outstanding trial results and retailer feedback.

Glen Mor has outstanding fruit quality, yield and flavour and due to its size and presentation, is economical to pick. Its large fruit size made choosing a name easy; Mor translates in old Scots as large, big or great.Glen Mors flavour is described by breeder, Nikki Jennings, as, Fruity and sweet, but with a balance of acid and notes of coconut.

Glen Mor is the result of a floricane x primocane cross and has benefits from both growth habits, including a lower chill requirement compared with other floricane varieties. Glen Mor also produces straight, spinefree long cane with a short internode length which makes it productive and easy to manage. Glen Mors excellent shelf-life score goes hand in hand with fantastic retailer feedback.

Speaking about Glen Mors release, Nikki says, We are very excited to release Glen Mor as our first variety with the root rot marker, combining resistance with superior commercial quality. Root rot resistance offers growers the option to return to soil production which makes plants much easier to manage at a lower cost.

Testing for the for Rub118b marker is now standard for promising seedlings from the James Hutton Limited breeding programme. Glen Mor plants are available now from RW Walpole and Genson BV in the EU, and from Global Plant Genetics and Meiosis in select territories out with the EU.

More technical information about Glen Morcan be found here.

Source: James Hutton.

Excerpt from:
"Glen Mor; the new raspberry that gives more" - hortidaily.com

Read More...

Largest study of prostate cancer genomics in Black Americans ids targets for therapies – Newswise

Friday, July 10th, 2020

Newswise Black men in the United States are known to suffer disproportionately from prostate cancer, but few studies have investigated whether genetic differences in prostate tumors could have anything to do with these health disparities.

Now, in the largest study of its kind to date, researchers from Boston University School of Medicine (BUSM), UC San Francisco (UCSF), and Northwestern University have identified genes that are more frequently altered in prostate tumors from men of African ancestry compared to other racial groups, though the reasons for these differences is not known, the authors say. None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, the authors say, as long as the therapies are applied equitably.

The newly identified gene variants could potentially lead to precision prostate cancer therapies specifically focused on men of African ancestry, and will inform broader efforts by the National Cancer Institute's RESPOND study to link gene variants to health outcomes in an even larger cohort of Black patients nationwide.

Despite declines in mortality related to cancer in the U.S., disparities by race have persisted. One in every six Black Americans will be diagnosed with prostate cancer in their lifetime, and these men are twice as likely to die from the disease as men of other races. But it is not yet clear to researchers whether differences in prostate cancer genetics contribute to these health disparities in addition to the social and environmental inequities known to drive poorer health outcomes across the board.

To date, studies trying to figure out what genes are commonly mutated in prostate cancers often have had very few samples from racial/ethnic minority groups despite the greater burden of prostate cancer in these populations. In May, the FDA approved a class of drugs known as PARP inhibitors as a therapy for men with prostate cancers driven by specific genetic mutations, but it is not known how prevalent these mutations are in people of African descent. As more genetic health studies are performed in minority populations, it has become clear that other genetically targeted therapies that have been developed based on studies of patients of European descent are at times much less effective, and in some cases cause dangerous side-effects, in other racial and ethnic groups.

In the new study, published July 10, 2020 inClinical Cancer Research, a journal of the American Association for Cancer Research, the research team set out to better understand differences in the mutations driving prostate cancer tumors in Black Americans compared to European Americans, and whether any such differences could influence disease outcomes or the effectiveness of PARP inhibitors or other targeted therapies.

The researchers collected and analyzed DNA sequencing data from previously published studies and from a commercial molecular diagnostics company. In total, they examined mutational patterns in prostate cancers from more than 600 Black men, representing the largest such study of this population to date.

The team found that the frequency of mutations in DNA repair genes and other genes that are targets of current therapeutics are similar between the two groups, suggesting that at least these classes of current precision prostate cancer therapies should be beneficial in people of both African and European ancestry, according to corresponding author Franklin Huang, MD, PhD, an assistant professor in UCSF's Division of Hematology/Oncology and member of the UCSF Helen Diller Family Comprehensive Cancer Center, UCSF Institute for Human Genetics, and UCSF Bakar Computational Health Sciences Institute.

While the researchers found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, they did identify other genes, such as ZFXH3, MYC, and ETV3, that were more frequently mutated in prostate cancers from Black men.

"These results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups and that samples from Black Americans need to be included in future molecular studies to fully understand these differences," said co-corresponding author Joshua Campbell, PhD, assistant professor of medicine at BUSM.

"The poorer health outcomes we see in Black men with prostate cancer are not easily explained by any of the distinct gene mutations we identified in prostate tumors from men of African ancestry. This highlights the need to examine the environmental and social inequities that are well known to influence health outcomes across the board," Huang added. "On the other hand, our tumor genomic analysis also showed that current precision medicine approaches ought to be as effective in Black Americans as they have been for other groups -- if we can ensure that these drugs are applied equitably going forward."

Developing a comprehensive understanding of how tumor genomics and other biological factors interact with social and environmental inequities to drive poorer clinical outcomes for Black prostate cancer patients should be an important priority for the efforts to improve precision medicine for these patients, the researchers say.

"These types of studies will remain important to understand when certain therapies may preferentially benefit Black patients, who continue to remain underrepresented in clinical trials," Campbell said.

In particular, the results will inform the efforts of the NCI-funded RESPOND Study. RESPOND provided funding for the new UCSF-BUSM-Northwestern study to guide its efforts to perform targeted gene sequencing in tumors from an even larger cohort of Black prostate cancer patients, said Huang, who leads RESPOND's tumor genetics studies based at UCSF. Through partnerships with Black communities across the country, RESPOND aims to recruit 10,000 Black prostate cancer patients in an effort to better understand the drivers of the disease's outsize burden among Black Americans.

"Previous studies have looked in isolation at different biological, social and environmental drivers of well-known racial disparities in prostate cancer," Huang said. "RESPOND is a nationwide effort to integrate all these components and ultimately identify specific steps that can be taken to eliminate prostate cancer's unequal burden in Black communities."

###

About UCSF:The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes UCSF Health, which comprises three top-ranked hospitals, as well as affiliations throughout the Bay Area. Learn more athttps://www.ucsf.edu, or see our Fact Sheet.

About BUSM:Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine (BUSM) today is a leading academic medical center with an enrollment of more than 700 medical students and 950 students pursuing degrees in graduate medical sciences. BUSM faculty contribute to more than 950 active grants and contracts, with total anticipated awards valued at more than $693 million in amyloidosis, arthritis, cardiovascular disease, cancer, infectious diseases, pulmonary disease and dermatology, among other areas. The School's teaching affiliates include Boston Medical Center, its primary teaching hospital, the Boston VA Healthcare System, Kaiser Permanente in northern California, as well as Boston HealthNet, a network of 15 community health centers. For more information, please visithttp://www.BUSM.bu.edu/busm/.

Continue reading here:
Largest study of prostate cancer genomics in Black Americans ids targets for therapies - Newswise

Read More...

Focusing on the common good in town hall, Yale leaders look toward fall – Yale News

Friday, July 10th, 2020

President Peter Salovey and fellow campus leaders convened a virtual town hall July 9, pointing the way forward as Yale charts its course for the coming academic year.

The hour-long livestreamed event, the second of two scheduled presidential town halls, touched on a host of topics, including campus health and safety measures, asymptomatic COVID-19 screening, child care, work-study arrangements, shuttle bus services, thecancellation of fall sports, and the federal governments recent directive regarding international students.

Above all, Salovey said, the Yale community must pull together in a socially-distanced way to preserve public health while also holding true to Yales mission of teaching and research.

Teaching and learning. Scholarship and research. These are essential to Yale being Yale, Salovey said. Im asking each of you, personally, for your help.

Arecording of the eventis posted on the presidents website.

Extensive details about the universitys plans for the 2020-21 academic year are available on itsmain COVID-19 website.

Joining Salovey for the town hall were Scott Strobel, provost and Henry Ford II Professor of Molecular Biophysics and Biochemistry; Nancy Brown, the Jean and David W. Wallace Dean of the Yale School of Medicine and C.N.H. Long Professor of Internal Medicine; Jack Callahan Jr., senior vice president for operations; Marvin Chun, dean of Yale College and the Richard M. Colgate Professor of Psychology; Lynn Cooley, dean of the Graduate School of Arts and Sciences and C.N.H. Long Professor of Genetics; Tamar Gendler, dean of the Faculty of Arts and Sciences and Vincent J. Scully Professor of Philosophy; and Kim Goff-Crews, secretary and vice president for university life.

Together, Yales leaders fielded more than 30 representative questions, taken from more than 900 submitted by 600 members of the Yale community before and during the event. Most questions sought amplification or clarification ofdecisions announced on July 1, when Yale invited students to return for the 2020-21 academic year.

First-year students, juniors, and seniors may be on campus for the fall semester; sophomores, junior, and seniors for the spring semester. Graduate and professional school students may return for the full year.

Undergraduates have the option of taking a leave of absence or gap year. Those first-year and sophomore students who enroll for both semesters of the upcoming academic year, including a remote semester, have the option of taking two free courses in Yale Summer Session 2021.

Yale will conduct mandatory COVID-19 testing for all students, who will further be required to sign a community compact pledging to follow university and public health guidance and protocols such as social distancing and wearing protective masks.

During the town hall, Salovey said Yale will announce specific enforcement measures for the community compact by the end of August.

This is a moment when we can all focus on the common good, he said.

Yale aims to announce its plans for the spring semester by early November, he said.

Salovey also stated vigoroussupport for Yales international students, noting that Yale will join an amicus brief in a lawsuit against the U.S. Department of Homeland Security regarding a recent policy that would potentially keep many such students from studying at U.S. universities.

Calling the policy deeply troubling, the president said Yales hybrid plan to conduct both online and in-person classes meets DHS requirements.

Strobel fielded several questions relating to child care, tuition, and travel for researchers doing field work.

We recognize these challenges are great, the provost said, acknowledging that many members of the Yale community are balancing work and child care responsibilities. Strobel said Yale has extended its benefits for child care options.

Strobel said Yale is not offering tuition reduction for the coming year, but said room and board costs will be lower than usual due to the adjusted academic calendar. And he noted the availability of the free summer courses.

As for fieldwork, Strobel said researchers whose projects require travel may request an exception to Yale travel restrictions now in place.

Many questions at the town hall centered around Yales efforts to ensure public health and safety.

Brown said Yale will continue to follow all national, state, and local guidance regarding COVID-19. In addition, she said Yale is tracking trends in new COVID-19 cases and monitoring rates of infection.

Yale is lowering risk of infection for students, faculty, and staff by reducing the density of people in classrooms, labs, libraries, and residential colleges, the medical school dean said. This includes upgrading certain ventilation systems, stepping up cleaning protocols, and adjusting the flow of foot traffic inside buildings.

Brown said the required COVID-19 screening will be more frequent for undergraduates than for graduate students because undergraduates typically live in closer proximity. She said Yale is conducting some of its screening with shorter nasal swabs, which can be self-administered under the supervision of a health care professional.

Details of Yaleshealth and safety guidelinesare available online.

Chun answered several questions about student life on campus for the 2020-21 academic year.

He said priority for on-campus attendance went to Yale College seniors, because this will be their final year on campus. Juniors were also invited to be on campus for the full year, he said, because junior year is a pivotal year for students to deepen work in their majors.

Yales cultural centers and most campus facilities will be open, Chun said; undergraduates will have the opportunity to conduct research on campus and remotely; students taking a semester or the full year off will not be able to participate in work study due to federal rules, but will have access to Yale career services.

Chun said students who take a semester or year off will be allowed to take part in commencement ceremonies with their original class.

He also assured students that public safety measures will allow for camaraderie, socializing, and the daily ebb and flow of campus life, even if daily routines are different.

You will be able to fully interact with your amazing friends, he said.

Goff-Crews said departments across Yale will directly address issues of inclusion and diversity, and that related events will be announced this summer. Yales support of Black, brown, Asian, and LGBTQ students, faculty, and staff is of paramount importance, she said.

She added that Yale is in the process of updating campus policing policies, including who will respond to emergency calls unrelated to criminal activity.

Several town hall questions focused on faculty recruitment and teaching.

Gendler said Yale remains fully engaged in recruiting and retaining premier faculty. She said new faculty hires will reflect Yales commitment to faculty diversity and excellence, key academic priorities, and the recruitment of the next generation of talented scholars. The university will offer an exceptional student-faculty ratio.

Gendler said Yale is supporting faculty during the pandemic by, among other things, providing innovative online teaching guidance through the Poorvu Center for Teaching and Learning and by matching faculty who need research support with graduate students in need of research opportunities.

Gendler also highlighted the learning environment students will experience this year. Many faculty across campus are adding extra sessions of the most popular classes, developing creative ways to have small-group interactions, and inviting an array of authors, composers, and experts to take part in teaching activities.

The individual attention students will get will be extraordinary, Gendler said.

At the end of the town hall, Salovey encouraged students, faculty, and staff to follow updates on YaleNews and Yales COVID-19 website throughout the summer.

To fight COVID-19, we need to do it as a unified community, he said. Thats what Yale is all about.

See more here:
Focusing on the common good in town hall, Yale leaders look toward fall - Yale News

Read More...

Lung Cancer in Non-smokers May Respond Differently to Treatment – Technology Networks

Friday, July 10th, 2020

Lung cancer in non-smokers is a diverse and distinct disease from that in smokers, and is likely to respond differently to targeted treatments, a major new study shows.Scientists studied a population in Taiwan with high rates of lung cancer among non-smokers and found a range of genetic changes which varied depending on a patients age or sex.

Many non-smokers with lung cancer had signs of DNA damage from environmental carcinogens, with young women in particular having particular genetic changes which are known to drive cancer to evolve aggressively.

The study which was co-led by scientists at The Institute of Cancer Research, London, alongside colleagues in Taiwan could lead to new treatments for non-smokers with lung cancer tailored to the newly identified genetic changes.

The research, published in the prestigious journal Cell today (Thursday), is the most comprehensive ever study of the biology of lung cancer in non-smokers. It was funded by Cancer Research UK and various institutions in Taiwan including the Ministry of Science and Technology.

Scientists at The Institute of Cancer Research (ICR) worked with colleagues at the Academia Sinica and the National Taiwan University to analyse tumour samples from 103 lung cancer patients from Taiwan the majority of whom were non-smokers.

Around 10-15 per cent of lung cancers in the UK occur in people who have never smoked but in East Asia, the proportion of lung cancers that occur in non-smokers is much higher, especially among women.

The researchers conducted a detailed analysis of genetic changes, gene activation, protein activity and cellular switches in lung cancer to develop the most comprehensive overview of the biology of disease in non-smokers to date.

Looking at the genetics and the related proteins produced by cancer cells in the tumour samples, scientists found that some early-stage lung tumours in non-smokers were biologically similar to more advanced disease in smokers.

Tumours in women often had a particular fault in the well-known lung cancer gene EGFR, whereas in men the most common faults were in the KRAS and APC genes. These differences could affect the response to targeted drugs in men and women.

Picking out people with late-like early-stage lung tumours could help guide treatment decisions, and patients could be monitored more closely for signs of their disease progressing.

The study found a pattern of genetic changes involving the APOBEC gene family in three-quarters of tumours of female patients under the age of 60, and in all women without faults in the EGFR gene.

APOBEC proteins play an important role in the function of the immune system but they can be hijacked by cancers, speeding up evolution and the emergence of drug resistance, a key area of study in the ICRs new Centre for Cancer Drug Discovery.

Patients without EGFR faults tend to do better on immunotherapy, and so testing for APOBEC could help pick out women more likely to respond to this form of treatment.

The team also picked out groups of patients particularly among older women whose cancers had mutation patterns linked to cancer-causing substances in their environment such as pollutants.

Finally, the team identified 65 proteins that were overactive in lung tumours that matched with existing candidate drugs. They found that one protein that cuts away at the surrounding tissue, called MMP11, was linked to poorer survival and could be explored as a marker for early detection.

While the new study looked at patients treated in Taiwan, the researchers believe that many of their findings could be applicable to UK patients. Next, they will be validating their findings in larger studies and beyond Asia.

Dr Jyoti Choudhary, Team Leader in Functional Proteomics at The Institute of Cancer Research, London, said:

We carried out the most comprehensive study ever conducted into the biology of lung cancers in an East-Asian population with a high proportion of non-smokers, and found that their disease is molecularly diverse, and distinct from what we classically see in smokers.

We found distinct patterns of genetic faults in non-smokers and between women and men, which suggest that a woman who has never smoked, for example, is likely to respond differently to treatment than a male smoker.

Some early-stage lung tumours had molecular features that are much more like that typically seen in later-stage disease which could help us more accurately diagnose patients with aggressive disease, and inform treatment strategies.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

This new study offers a deep dive into the biology of lung cancer in people who have never smoked. It reveals new ways of telling apart patients with different tumour characteristics that could be exploited with tailored treatment strategies.

Lung cancer is the biggest cancer killer in the UK, and much of what we know about the disease comes from studies in smokers. Im hopeful that the new insights gleaned in this new study will really step up precision medicine in lung cancer for non-smokers, so they can be offered smarter, kinder treatment options.

Dr Emily Armstrong, research information manager at Cancer Research UK, said:

In order to beat cancer, we need to understand all the ways it can develop. This research highlights just how much cancers can vary between people depending on their lifestyle and environment. Understanding the difference between lung cancers in smokers and non-smokers could be vital for providing patients with the most appropriate treatment.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

View post:
Lung Cancer in Non-smokers May Respond Differently to Treatment - Technology Networks

Read More...

Six months of coronavirus: the mysteries scientists are still struggling to solve. – The Yucatan Times

Friday, July 10th, 2020

From immunity to the role of genetics, the prestigious scientific journal Nature examines five pressing questions about COVID-19 that researchers are addressing.

UNITED STATES (Reuters) To mark six months since the world first learned of the disease responsible for the pandemic, Nature looks at some of the key questions researchers have yet to answer.

In late December 2019, reports emerged of mysterious pneumonia in Wuhan, China, a city of 11 million people in the southeastern province of Hubei. The cause, Chinese scientists, quickly determined, was a new coronavirus distantly related to the SARS virus that had emerged in China in 2003, before spreading globally and killing nearly 800 people.

Six months and more than 10 million confirmed cases later, the VID-19 pandemic has become the worst public health crisis in a century. More than 500,000 people have died worldwide. It has also catalyzed a revolution in research, as scientists, physicians, and other academics have worked at breakneck speed to understand COVID-19 and the virus that causes it: SARS-CoV-2.

They have learned how the virus enters and hijacks cells, how some people fight it, and how it eventually kills others. They have identified drugs that benefit the sickest patients, and many more potential treatments are being developed. They have developed nearly 200 potential vaccines, the first of which could be proven effective by the end of the year.

But for every idea of COVID-19, more questions arise, and others persist. This is how science works. To commemorate six months since the world first learned of the disease responsible for the pandemic, the science journal Nature looks at some of the key questions that researchers do not yet have answers to.

1. Why do people respond so differently?Some people never develop symptoms, while others, some apparently healthy, have severe or even fatal pneumonia.

One of the most striking aspects of COVID-19 is the marked differences in the experiences of the disease. Some people never develop symptoms, while others, some apparently healthy, have severe or even fatal pneumonia. The differences in clinical outcome are dramatic, says Kri Stefnsson, a geneticist and CEO of DeCODE Genetics in Reykjavik, whose team is looking for human gene variants that may explain some of these differences.

That search has been hampered by the relatively small number of cases in Iceland. But last month, an international team that analyzed the genomes of approximately 4,000 people in Italy and Spain discovered the first strong genetic links to severe COVID-19. People who developed respiratory failure were more likely to carry one of two particular genetic variants than people without the disease.

One variant lies in the region of the genome that determines the ABO blood type. The other is close to several genes, including one that encodes a protein that interacts with the receptor the virus uses to enter human cells, and two others that encode molecules linked to the immune response against pathogens. The researchers are part of the COVID-19 Host Genetics Initiative, a global consortium of groups that are pooling data to validate the findings and discover more genetic links.

The variants identified so far appear to play a modest role in the outcome of the disease. A team led by Jean-Laurent Casanova, an immunologist at Rockefeller University in New York City, is looking for mutations that will play a larger role. His team is combining the entire genomes of otherwise healthy people under 50 who have experienced severe cases of COVID-19, he says, such as the guy who ran a marathon in October and now, five months later, is in the ICU, intubated and ventilated. Extreme susceptibility to other infections, such as tuberculosis and Epstein-Barr virus, a generally harmless pathogen that sometimes causes serious illness, has been attributed to mutations in individual genes. Casanova suspects that the same will be true for some cases of COVID-19.

2. What is the nature of immunity, and how long does it last?Researchers do not yet know what level of neutralizing antibodies is needed to fight SARS-CoV-2 reinfection or reduce the symptoms of COVID-19 in a second illness.

Immunologists are working feverishly to determine what immunity to SARS-CoV-2 might look like and how long it might last. Much of the effort has focused on neutralizing antibodies, which bind to viral proteins and directly prevent infection. Studies have found that levels of neutralizing antibodies to SARS-CoV-2 remain high for a few weeks after infection and begin to decline.

However, these antibodies may remain at high levels longer in people who had particularly severe infections. The more virus, the more antibodies and the longer they last, says immunologist George Kassiotis of the Francis Crick Institute in London. Similar patterns have been seen with other viral infections, including SARS (severe acute respiratory syndrome). Most people with SARS lost their neutralizing antibodies after the first few years. But those who had it severely still had antibodies when they were re-tested 12 years later.

Researchers do not yet know what level of neutralizing antibodies is needed to fight SARS-CoV-2 reinfection, or at least to reduce the symptoms of SARS-CoV-19 in a second illness. And other antibodies may be essential for immunity. Virologist Andres Finzi, of the University of Montreal in Canada, plans to study the role of antibodies that bind to infected cells and mark them for execution by immune cells, a process called antibody-dependent cellular cytotoxicity, in response to SARS-CoV-2.

Ultimately, a complete picture of immunity to SARS-CoV-2 is likely to extend beyond the antibodies. Other immune cells called T cells are essential for long-term resistance, and studies suggest that SARS-CoV-2 is also urging them to arms. People equate antibodies with immunity, but the immune system is such a wonderful machine, Finzi explains. Its much more complex than just antibodies.

Because there is not yet a clear, measurable marker in the body that correlates with long-term immunity, researchers must reconstruct the mosaic of immune responses and compare it to responses to infections with other viruses to estimate how long the protection might last. Studies of other coronaviruses suggest that sterilizing immunity, which prevents disease, may last only a few months. But protective immunity, which can prevent or alleviate symptoms, may last longer than that, warns Shane Crotty, a virologist at the La Jolla Institute of Immunology in California.

3. Has the virus developed any mutations of concern?The versions of the coronavirus identified at the beginning of outbreaks in hot spots such as Lombardy in Italy or Madrid, for example, may appear more lethal than those found in later stages or elsewhere (AFP)

All viruses mutate as they infect people, and SARS-CoV-2 is no exception. Molecular epidemiologists have used these mutations to track the global spread of the virus. But scientists are also looking for changes that affect their properties, such as making some lineages more or less virulent or transmissible. Its a new virus; if it became more severe, thats something Id like to know, says David Robertson, a virologist at the University of Glasgow, UK is cataloging mutations in SARS-CoV-2. Such mutations also have the potential to diminish vaccines effectiveness by altering the ability of antibodies and T cells to recognize the pathogen.

But most of the mutations will have no impact, and choosing the ones of concern is a challenge. Versions of the coronavirus identified at the beginning of outbreaks in hot spots such as Lombardy in Italy or Madrid, for example, may appear more lethal than those found at later stages or elsewhere. But such associations are probably spurious, says William Hanage, an epidemiologist at Harvard Universitys TH Chan School of Public Health in Boston, Massachusetts: health officials are more likely to identify severe cases in the early, uncontrolled stages of an outbreak. The widespread of specific mutations could also be due to founder effects, in which lineages that emerge early in transmission centers such as Wuhan or northern Italy have a mutation that is transmitted when outbreaks spread elsewhere.

Researchers are debating whether the widespread prevalence of a mutation in the spike protein of the virus is a product of a founder effect or an example of a consequent change in the biology of the virus.

The mutation appears to have emerged around February in Europe, where most circulating viruses now carry it and are now found in all regions of the world. Several pre-print studies have suggested that this mutation makes the SARS-CoV-2 virus more infectious to cultured cells, but it is not clear how this property translates into humans.

4. How well will a vaccine work?With governments and industry injecting billions into the development, testing, and manufacturing of vaccines, scientists say vaccines could be available in record time. It may not be fully capable.

An effective vaccine may be the only way out of the pandemic. There are currently approximately 200 in development worldwide, with about 20 in clinical trials. The first large-scale efficacy trials to determine whether any vaccine works will begin in the coming months. These studies will compare rates of infection with COVID-19 among people receiving a vaccine and those receiving a placebo.

But there are already clues in the data from animal studies and early human trials, mainly safety tests. Several teams have conducted challenge tests in which animals receiving a candidate vaccine are intentionally exposed to SARS-CoV-2 to see if it can prevent infection. Studies in macaque monkeys suggest that vaccines may do a good job of preventing lung infection and resulting pneumonia, but not blocking infection in other parts of the body, such as the nose. Monkeys that received a vaccine developed by the University of Oxford, UK, and were then exposed to the virus had viral genetic material in their noses comparable to levels in unvaccinated animals. Results like this increase the chance of a COVID-19 vaccine preventing severe disease, but not the spread of the virus.

Data in humans, although scarce, suggest that COVID-19 vaccines cause our bodies to produce potent neutralizing antibodies that can block infection of the virus by cells. It is still unclear whether the levels of these antibodies are high enough to stop new infections or how long these molecules persist in the body.

With governments and industry injecting billions into the development, testing, and manufacturing of vaccines, scientists say, a vaccine may be available in record time, but it simply may not be fully effective. We could have vaccines in the clinic that are useful in people within 12 or 18 months, Dave OConnor, a virologist at the University of Wisconsin-Madison, told Nature in May. But were going to need to improve them.

5. What is the origin of the virus?Most researchers agree that the SARS-CoV-2 coronavirus probably originated in bats, specifically horseshoe bats. This group is home to two coronaviruses closely related to SARS-CoV-2. One, called RATG13, was found in intermediate Horseshoe bats (Rhinolophus affinis) in southwestern Chinas Yunnan Province in 2013. Its genome is 96% identical to SARS-CoV-2. The next closest match is RmYN02, a coronavirus found in Malayan horseshoe bats (Rhinolophus malayanus), which shares 93% of its genetic sequence SARS-CoV-2.

A comprehensive analysis of more than 1,200 coronaviruses sampled from bats in China also points to the Horseshoe bats in Yunnan as the likely origin of the new coronavirus. But the study does not exclude the possibility that the virus originated from horseshoe bats in neighboring countries, including Myanmar, Laos, and Vietnam.

The 4% difference between the genomes of RATG13 and SARS-CoV-2 represents decades of evolution. Researchers say this suggests that the virus may have passed through an intermediate host before spreading to people, just as it is believed that the virus causes SARS to pass from horseshoe bats to civets before reaching people. Some candidates for this animal host appeared at the beginning of the outbreak, and several groups focused on pangolins.

Researchers isolated coronaviruses from Malaysian pangolins (Manis javanica) confiscated during anti-smuggling operations in southern China. These viruses share up to 92% of their genomes with the new coronavirus. Studies confirm that pangolins may harbor coronaviruses that share a common ancestor with SARS-CoV-2, but do not prove that the virus jumped from pangolins to people.

To uniquely track the virus journey to people, scientists would need to find an animal that harbors a more than 99% similar version of SARS-CoV-2, a perspective complicated by the fact that the virus has spread so widely among people that they, in turn, passed it on to other animals, such as cats, dogs, and farm minks.

Zhang Zhigang, an evolutionary microbiologist at Yunnan University in Kunming, says efforts by research groups in China to isolate the virus from livestock and wildlife, including civets, have been uncovered. Groups in Southeast Asia are also looking for the coronavirus in tissue samples from bats, pangolins, and civets.

The Yucatan TimesNewsroom

comments

Read this article:
Six months of coronavirus: the mysteries scientists are still struggling to solve. - The Yucatan Times

Read More...

World-Renowned Transplant Surgeon to Lead Department of Surgery at NYU Langone Health – NYU Langone Health

Thursday, July 9th, 2020

Robert Montgomery, MD, DPhil, a pioneering surgeon and director of the NYU Langone Transplant Institute, has been appointed chair of the Department of Surgery. He will assume his new post on September 1. H. Leon Pachter, MD, the George David Stewart Professor of Surgery, who has had a distinguished tenure as chair of the department since 2007, will remain a member of the faculty as chair emeritus.

An internationally renowned surgeon, Dr. Montgomery joined the faculty of NYU Grossman School of Medicine in 2016 from The Johns Hopkins Hospital, where he was part of the team that pioneered a laparoscopic technique for procuring a kidney for live donation that is now standard practice. Under his leadership, the Transplant Institute at NYU Langone has been developing innovative protocols and making significant contributions toward increasing the availability of organs for transplant.

Dr. Montgomery made major headlines himself when, in 2018, the team he assembled performed a heart transplant on him. In yet another example of the game-changing advances he is helping bring about, he accepted a heart that was positive for hepatitis Corgans for which he has strongly advocated for other recipients, including those in the heart, lung, kidney, and liver programs. Thanks to protocols he helped develop, these organs can now be made safe with antiviral medications.

Before joining NYU Langone, Dr. Montgomery developed a system of multiway donor exchanges, also called domino exchanges, facilitating transplants when an intended organ recipient has a donor who is incompatible. He has created techniques such as desensitization therapy to reduce the risk of organ rejection, and has performed groundbreaking research on the possible use of organs from genetically modified animals to address the dire shortages of organs available for transplant.

Dr. Montgomery has made a name for himself in the field of transplant surgery, not only as an innovator and leader, but as a grateful patient, says Robert I. Grossman, MD, dean and CEO of NYU Langone. Under his leadership, the Department of Surgery will continue to push the envelope on behalf of our patients to ensure we continue to provide world-class care.

We thank Dr. Pachter for his leadership of the department, which saw tremendous growthtripling in size during his tenure, says Dr. Grossman. His commitment to patients, trainees, and his faculty embodies the principles of a great leader and outstanding physician.

After graduating magna cum laude with a bachelor of science in biology from St. Lawrence University, Dr. Montgomery graduated with honors from the University of Rochester School of Medicine, and received his doctor of philosophy in molecular immunology from Balliol College at the University of Oxford, England. He completed his general surgical training, postdoctoral fellowship in human molecular genetics, and transplantation surgery fellowship at The Johns Hopkins Hospital.

A prolific researcher and educator, Dr. Montgomery has authored or co-authored more than 275 peer-reviewed publications (cited more than 25,000 times) and given 250 invited or named lectures. In addition to his many academic honors and distinctions, including a Fulbright Scholarship and a Thomas J. Watson Fellowship, in 2019 the Greater New York Hospital Association presented him with the Profile in Courage Award. He appears in the 2010 Guinness Book of World Records for the most kidney transplants performed in one day.

The Department of Surgery at NYU Langone enjoys a distinguished history of discovery and innovation, which has been further enhanced under the exemplary leadership of Dr. Leon Pachter, Dr. Montgomery says. I am extremely excited to accept this new position, and I look forward to this extraordinary opportunity to advance NYU Langones trifold commitment to education, research, and clinical care.

Rob MagyarPhone: 212-404-3500robert.magyar@nyulangone.org

Follow this link:
World-Renowned Transplant Surgeon to Lead Department of Surgery at NYU Langone Health - NYU Langone Health

Read More...

Researchers at U of T use stem cells to grow functional blood vessel cells found in liver – News@UofT

Thursday, July 9th, 2020

An inter-disciplinary team of researchers, funded by the University of Torontos Medicine by Design,hasgeneratedfunctional blood vessel cells found in the liver from stem cells a discovery thatoffersan opportunityto study the rolethe cellsplayin liver developmentand diseaseprogression, and which couldlead tonew therapies to treat hemophilia A.

Thestudy, titledGeneration of Functional Liver Sinusoidal Endothelial Cells from Human Pluripotent Stem Cell-Derived Venous Angioblasts,waspublished this week in Cell Stem Cell. Itrepresents a collaborative effort betweenbasic and clinical researchersat U of T and the University Health Network (UHN)with expertise in stem celland computationalbiology,human liver physiology and functionand liver transplantation.

It alsodraws onprevious Medicine by Design-funded research that led to the creationin 2018of the first single-cell map of the human liver.

By combining insights from developmental biology and liver anatomy with thecellatlasof the human liver,we were able to generateand validatefunctional human liver vasculature from stem cells, saysBlair Gage,apost-doctoral researcher at the McEwen Stem Cell Institute at UHNand lead author ofthestudy.Nowwe canmove forwardto use these liver endothelial cells tobetterunderstandtheir role in liver functionand to develop new therapies to treat disorderssuch ashemophilia A.

Theinterdisciplinary researchteam also includes:JeffLiu,research associate atU of TsDonnelly Centrefor Cellular andBiomolecularResearch;Brendan Innes, a PhD candidate at the Donnelly Centre and in thedepartment ofmolecular genetics in the Faculty of Medicine;Sonya MacParland, scientist in themulti-organ transplant program at theToronto General Hospital Research Institute andan assistant professor in U of Ts departments of immunology andlaboratory medicine and pathobiology; Ian McGilvray,senior scientist at themulti-organ transplant program at theToronto General Hospital Research Institute and a professorinU of Ts department of surgery;Gary Bader, professor at the Donnelly Centreandthedepartment ofmolecular genetics; andGordon Keller,director andsenior scientist at theMcEwen Stem Cell Institute at UHNandprofessor in U of Ts department of medical biophysics.

Researchersinthe Keller lab had the goal of generatinga functional liver vasculature cell type known as liver sinusoidal cells (LSECs)fromhuman pluripotent stem cells (hPSCs) cells that can self-renew and have the potential to turn into any other cell type in the human body. LSECs are essential for normal liver function and represent the main source of factor VIII,a blood-clotting protein that is missing or defective in patients with hemophilia A.

However, the teamhad todemonstratethatthecellstheyhadmadein the labhad thesamespecializedgenetic and functionalfeaturesasthose in thehuman liver.So they turned to the work of MacParland, Bader and McGilvray,whoin the first phase ofMedicine by Designs team projectfundingdescribed amolecularmap of the cell types in the adult liver.Thatresearchhascontributed totheHuman Cell Atlasan international effort to create comprehensive reference maps of all human cellsand last yearattracted follow-on funding from the Chan Zuckerberg Initiative.

This paper uses our human liver map as a guide to know if the cells beinggeneratedaretherightones through collaboration with Gary Baders group, says MacParland.The work really highlights thestrengthof MedicinebyDesignin bringingtogether researchers from multiple institutionstofocus on a common goal.

With Bader and Lius help, Keller lab researchers were able to use the MacParlandhuman livermapto show that thehPSC-derivedendothelialcellsthey had generatedshared manyof thefeatures found innormal liver vasculature. The Keller lab team then brought Innes on board toformat thedatafromthehPSC-derived LSECsfor the research communitytoeasilyexplorethe molecular profile of these cells.

This research was supported by Medicine by Design, which receives funding from the federal governmentsCanada First Research Excellence Fundand by theCanadian Institutes of Health Research.

The work continues in a current Medicine by Design-funded team projectled by Kellerthat aims to make other key liver cell types and put together the pieces to get functional tissueswith the goal of developing new cell-based therapies for liver-related diseases.That project is part ofanew $20-million round of team project fundingthat Medicine by Design announced late last year.

Medicine by Designbrings togetherinvestigatorsfromdifferent disciplinesatU of T and its affiliated hospitals to advance new discoveries in regenerative medicine and accelerate them toward clinical impact.Medicine by Designwill host ameeting of the Human Cell Atlass Development and Pediatric Atlasin July 2021in Toronto.

Read more:
Researchers at U of T use stem cells to grow functional blood vessel cells found in liver - News@UofT

Read More...

Gene yields insights into the causes of neurodegeneration | Cornell Chronicle – Cornell Chronicle

Thursday, July 9th, 2020

Across the globe, approximately 50 million people are living with dementia. The two most common forms are Alzheimers disease and frontotemporal lobar degeneration (FTLD), which develop when neurons in specific parts of the brain stop functioning triggering memory loss and other behavioral or personality changes.

Without a cure, the World Health Organization predicts that number could rise by as many as 10 million cases per year. However, predicting the onset of these diseases is tricky because neurodegeneration can start years before people present any outward symptoms.

An electron microscope shows the myelin sheath in a healthy mouse brain. The myelins fatty tissue insulates neurons and protects them from damage.

Cornell researchers including Fenghua Hu, associate professor in the Department of Molecular Biology and Genetics and member of the Weill Institute for Cell and Molecular Biology, are taking a closer look at the factors that cause Alzheimers, FTLD and similar diseases. Hus latest study, A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination, was published June 23 in the journal Brain.

I want to have a better understanding of the molecular and cellular mechanisms of neurodegeneration, Hu said. I hope that our research can facilitate therapeutic development of treatment options for patients suffering from neurodegenerative diseases and other brain disorders.

Her team started by investigating a specific gene, called TMEM106B, which had been previously identified as a risk factor for several neurodegenerative diseases, including Alzheimers and FTLD. Researchers also knew that a particular mutation in that gene caused a neurological defect known as hypomyelinating leukodystrophy, which creates a myelin deficit in the brain, leading to the deterioration of both motor skills and mental acuity.

Myelin is the fatty tissue that wraps around nerve fibers, or axons, in the nervous system. Like insulation, this tissue forms a sheath that surrounds the nerve fibers, protecting them from damage and allowing electrical impulses to be quickly transmitted along the nerve.

Hu wanted to see exactly how that one mutation in TMEM106B could cause so much damage. She also wanted to learn more about how the gene regulates the formation and maintenance of the myelin sheath under normal conditions.

We found that the mutation associated with the disease is a loss-of-function mutation, Hu said.

This distinction is critical since the Hu lab saw that TMEM106B is expressed in the cells that are responsible for forming the protective myelin tissue. Those cells are called oligodendrocytes, and within them, TMEM106B resides in the lysosome a tiny organelle that acts as a cellular recycling center.

Like the stomach, the lysosome must maintain a specific pH to keep its enzymes active. As oligodendrocytes build the myelin sheath, lysosomes remove any extraneous materials. They can also store myelins main membrane protein and deposit it in areas surrounding the nerve fibers.

Hus team discovered that the TMEM106B mutation prevented the gene from regulating both the pH inside the lysosome and the movement of the lysosome itself inhibiting the oligodendrocytes ability to build compact myelin layers.

Using a mouse model, Hu also noticed that an overall TMEM106B deficiency led to abnormal lysosome movement within the oligodendrocytes. This created defects in the myelin sheath, and the team observed behavioral changes, including poor motor coordination.

Additional research will examine the exact mechanism by which TMEM106B regulates lysosome function and will demonstrate how the mutation leads to the known neurological defects.

We want to explore whether the genes regulation of myelination contributes to its association with neurodegenerative diseases, including Alzheimers, FTLD and other age-related dementia, Hu said.

First author on the paper is postdoctoral associate Tuancheng Feng, and co-authors include other members of the Hu lab: Rory Sheng 19, Mohammed Ullah 21, Christina Mendoza 19, Isabel Iscol Katz 21, Daniel Paushter, Ph.D. 18, Peter Sullivan, Ph.D. 17, lab technician Xiaochun Wu, and former students Xiaolai Zhou and Laura Camila Martinez Enriquez.

Collaborators also include Fred Maxfield, professor in the Department of Biochemistry at Weill Cornell Medicine, and his research associate Santiago Domenech.

Hu received funding from the Bluefield project to cure frontotemporal dementia, National Institute on Aging, and National Institute of Neurological Disorders and Stroke.

Jana Wiegand is the editorial content manager for the College of Agriculture and Life Sciences.

See original here:
Gene yields insights into the causes of neurodegeneration | Cornell Chronicle - Cornell Chronicle

Read More...

Page 11«..10111213..2030..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick